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Cell-based insulin therapies can potentially improve glycemic regulation in insulin 
dependent diabetes patients and thus help reduce secondary complications. The long-term 
goal of our work is to engineer autologous insulin-secreting intestinal endocrine cells as a 
non- cell approach to alleviate donor cell shortage and immune rejection issues associated 
with islet transplantation. These cells have been chosen for their endogenous similarity to 
 cells, but generating cell constructs with sufficient insulin secretion for therapeutic effect 
has proven challenging. Previous work in our lab showed that a tissue engineered 
pancreatic substitute (TEPS) based on an engineered insulin-secreting L cell line, 
GLUTag-INS, was insufficient in affecting blood glucose levels in streptozotocin-induced 
diabetic mice, but promising since human insulin was detected in the blood. The objective 
of this project was therefore to fabricate an improved TEPS based on GLUTag-INS cells 
and evaluate its suitability as a standalone diabetes therapy. To achieve this objective, the 
following specific aims were (1) to investigate gene incorporation as a strategy to enhance 
recombinant insulin secretion from GLUTag-INS cells; (2) to develop and characterize a 
TEPS in vitro based on a microcapsule system containing improved GLUTag-INS cells 
with bioluminescence monitoring capability; and (3) to assess therapeutic efficacy of the 
graft in a diabetic, immune-competent mouse model and use bioluminescence monitoring 
to elucidate in vivo transplant behavior. This thesis therefore reports on the progression of 
studies from the genetic and molecular levels for improved insulin secretion per-cell, to the 
tissue level for enhanced secretion per-graft, and lastly to the preclinical level for 
therapeutic assessment in a diabetic mouse model.
 
1 
CHAPTER 1: INTRODUCTION 
 
In 2011, the Center for Disease Control (CDC) reported that 25.8 million people in 
the United States alone are affected with Diabetes, and 6.7 million of them are dependent 
on insulin [1]. To prevent long-term complications in patients with insulin dependent 
diabetes (IDD), blood glucose levels must be tightly regulated with multiple daily insulin 
injections or continuous subcutaneous insulin infusion (CSII) by pump [2]. Due to the 
numerous variables that affect blood glucose levels, this task is far from trivial and requires 
significant time from the patient. Even with diligent monitoring and insulin administration, 
many patients fail to achieve recommended control of their blood sugars. An IDD patient’s 
quality of life is burdened with dosing calculations, dietary and exercise restrictions, 
painful needles, and long-term complications. There is a clear need for a diabetes treatment 
that improves glycemic regulation without further burdening patients, to reduce morbidity 
and improve quality of life. 
 Cell-based treatments can potentially address these needs by allowing a one-time 
administration at the hospital requiring no work from the patient thereafter and providing 
a perpetual insulin reservoir regulated by physiological cues, similar to blood glucose 
regulation in a healthy body. Although this approach is indeed promising, there are 
challenges that must be resolved before a cell-based insulin therapy can become reality for 
diabetic patients. The most clinically successful cell therapy thus far is islet transplantation, 
but this approach is limited by human islet donor scarcity and immune rejection resulting 
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in limited durability [3]. These hurdles have motivated researchers to explore the 
possibility of using alternative cell sources. 
Substantial efforts have been put forth to use pig islets as the donor cell source to 
alleviate availability problems [4]. Encapsulation of pig islets within an inert biomaterial 
for xenogeneic transplantation is a strategy that, at least partially, provides protection from 
immune rejection [5]. Unfortunately, encapsulated pig islets have been shown in multiple 
cases to cause an immune response, in addition to rarely restoring normoglycemia, in 
higher order animals including humans [6-11]. They have, however, contributed to 
improving blood glucose regulation, if only for a short period of time. 
A non- cell source can potentially address both donor cell availability and immune 
rejection issues by allowing the cell source to be the diabetic patient’s own healthy cells. 
The overarching goal of this approach is to engineer a fraction of the patient’s cells into 
meal or glucose-responsive insulin secretors for transplantation back into the same patient. 
The most attractive non- cell candidates are cells that already possess key  cell 
characteristics and therefore require the least genetic manipulation. There are three 
enteroendocrine cell types that are inherently glucose or meal-responsive, possess a 
secretory mechanism like  cells, and express the prohormone convertases necessary for 
proinsulin to insulin processing: gastric G cells [12], intestinal L cells, and intestinal K 
cells [13]. The question is whether any of these cells really could be engineered for insulin 
production and behave similarly to  cells. 
The answer to this question is yes; initial proof-of-concept studies showed that mice 
transgenic for human insulin-secreting K cells were resistant to streptozotocin (STZ)-
induced diabetes [12]. Similarly, insulin-secreting G cells significantly reduced mouse 
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blood glucose levels [14]. However, since this transgenics approach is not viable for 
humans, the engineering of enteroendocrine cell lines became more popular for preclinical 
evaluation. Two groups reported therapeutic efficacy of K cell lines that were stably 
transfected with the insulin gene, selected for the highest insulin-secreting clones, and 
transplanted in diabetic mice [15, 16]. The problem with this approach is that it allowed 
for tumor formation due to uncontrollable cell growth and resulted in an insulin overload, 
i.e. chronic hypoglycemia, generally leading to death. Additionally, mice with no immune 
system were used as the preclinical model to avoid transplant rejection. Although these 
studies showed promise for an enteroendocrine cell therapy approach, they lacked clinical 
relevance. The question therefore remains whether a practical number of 
transplanted engineered enteroendocrine cells can safely alleviate diabetes in an 
immune-competent animal model. 
Encapsulating cells to control cell growth and provide immune protection for 
transplanting in immune competent diabetic mice began to address these issues. Unniappan 
et al. found that microencapsulated insulin-producing K cells were unable to control blood 
sugars until a drug-inducible element was incorporated into the insulin transgene [17]. 
Alternatively, Bara et al. seeded human insulin-secreting L cells (GLUTag-INS) in a 
macrocapsule device for transplantation [18-20]. Human insulin was detected in mouse 
plasma, but blood glucose levels were unaffected. Insufficient insulin secretion and 
macrocapsule limitations were two likely barriers that prevented these systems from 
serving as standalone diabetes treatments. Additionally, a lack of understanding regarding 




The overall objective of this thesis was to fabricate an improved tissue engineered 
pancreatic substitute (TEPS) based on enteroendocrine cells and evaluate its suitability as 
a standalone diabetes therapy. Improvements were three-fold: 1) insulin secretion 
enhancement of the previously developed GLUTag-INS cell line, 2) bioluminescence 
incorporation for direct, minimally invasive survival monitoring, and 3) alginate 
microencapsulation for higher overall insulin output per unit graft volume relative to the 
macrocapsule previously developed [19]. The following Specific Aims were completed to 
build the improved TEPS and transfer this project from the stage of development and 
characterization to preclinical therapeutic efficacy evaluation: 
 
Specific Aim 1: To investigate gene incorporation as a strategy to enhance recombinant 
insulin secretion from GLUTag-INS cells. 
Specific Aim 2: To develop and characterize a tissue engineered pancreatic substitute in 
vitro based on a microcapsule system containing improved GLUTag-INS cells with 
bioluminescence monitoring capability. 
Specific Aim 3: To assess therapeutic efficacy of the graft in a diabetic, immune-
competent mouse model and use bioluminescence monitoring to elucidate in vivo 
transplant behavior. 
 
Per-cell secretion improvements began at the genetic and molecular levels and are 
covered in CHAPTER 3, with a focus on identifying limiting steps in the L cell regulated 
secretory pathway (RSP) and developing novel methods for enhancing insulin secretion 
output per cell. A novel enhancement method was developed after studying the short and 
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long-term effects of additional human insulin transgene incorporation via lentiviral 
transduction and histone deacetylase inhibitor (HDACi) treatment on recombinant insulin 
secretion output per cell. To identify limiting steps in the RSP, this enhancement method 
was also used as a tool to alter intracellular activity and measure effects such as insulin 
mRNA, intracellular levels of proinsulin and insulin, and secreted levels of proinsulin and 
insulin. Increasing knowledge of these cells will better guide the field in pursuing the most 
feasible options for an enteroendocrine cell-based insulin therapy. 
Another limitation of the previous TEPS was its agarose disc configuration which 
resulted in a dramatic drop in the apparent insulin secretion rate per cell relative to secretion 
from unencapsulated cells grown on tissue culture plastic. Additionally, cell loading 
densities were limited and in vivo breakage may have caused the observed immune 
response. Alginate microcapsules have been used extensively in islet transplantation, 
appearing to have good diffusional capacity, to allow for high cell loading densities, and 
to better evade the immune system [21]. However, the application of this method to 
intestinal endocrine cells has been challenging, as demonstrated by Unniappan et al., and 
it is important for researchers to better identify key factors that influence graft survival in 
vivo. The effects of luciferase lentiviral transduction and alginate microencapsulation on 
the enhanced cell line developed in CHAPTER 3 are reported in CHAPTER 4. Insulin 
secretion output per unit graft volume and real-time monitoring capabilities were 
temporally evaluated, and therapeutic cell numbers were estimated to set the stage for 
therapeutic efficacy studies covered in CHAPTER 5. 
After making significant improvements to the TEPS in CHAPTERS 3 and 4, it was 
necessary to characterize in vivo bioluminescence and evaluate therapeutic efficacy in a 
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preclinical animal model, as reported in CHAPTER 5. The STZ-induced immune-
competent diabetic mouse model was chosen for preclinical animal studies. As previously 
mentioned, the immune-competent, versus incompetent, mouse is more clinically relevant 
because it allows for realistic testing of the immune protective effects of the alginate 
microcapsule configuration. This chapter reports on the blood glucose levels, exogenous 
insulin administration, body weight trends, and bioluminescence signals for 17 days after 
intraperitoneal injection of the TEPS into diabetic mice. TEPS were retrieved on day 17 
for live/dead, histology, metabolic activity, and insulin secretion measurements and 
analyses. 
Finally, CHAPTER 6 summarizes the conclusions drawn from these studies and 
discusses the practicality of using a non- cell TEPS as a standalone insulin therapy for 
diabetes. Additionally, potential future research directions are suggested in the context of 
supplemental and alternative methods that are the most promising in accelerating the 
development of a clinically acceptable cell-based insulin therapy.
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CHAPTER 2: BACKGROUND 
 
 Diabetes 
Diabetes is a group of chronic metabolic diseases characterized by casual blood 
glucose concentrations above 200 mg/dL due to the loss or impairment of insulin-
producing  cells. The long-term impact of the disease is the occurrence of complications 
such as heart disease, stroke, hypertension, blindness, kidney disease, and nervous system 
disease [1]. The terms Type 1 and Type 2 refer to two genetically distinct forms of diabetes 
[22]. Type 1 diabetes (T1D) is considered an autoimmune disease in which changes in 
certain immune regulatory genes cause T-cell mediated destruction of  cells [23, 24]. On 
the other hand, lifestyle as well as genetic variations are believed to play roles in the 
progression of Type 2 diabetes (T2D), causing a significant decline in  cell mass and 
function [25]. Although insulin resistance is an important factor in T2D, recent reports have 
shown that  cell dysfunction is the necessary and sufficient cause [26-28]. 
Diabetes is a major public health issue and the most frequent endocrine disease in 
industrialized countries [29].The most recent report from the Center for Disease Control 
(CDC) states that approximately 25.8 million people were affected with diabetes in the 
United States in 2011 and as of 2007, the economic burden totaled $174 billion. This 
burden was the result of costs from diabetes management, treatment of secondary 
complications, and subsequent productivity loss [30]. With the prevalence of diabetes 
doubling every ten years and an estimated 250 million people afflicted worldwide, better 
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therapies need to be developed to improve patient quality of life and reduce healthcare 
costs associated with the disease. 
 
 Insulinand cells 
Insulin is a 5.8 kDa peptide hormone that circulates through blood vessels to instruct 
the body’s cells to absorb glucose and consequently reduce glucose concentrations in the 
blood. Insulin is exclusively produced by endocrine  cells that make up 65-80% of the 
islets of Langerhans which reside in the pancreas. Islets are strategically connected to the 
vasculature and receive ten times more blood than exocrine cells of the pancreas to achieve 
high nutrient sensitivity. In  cells, the hormone is first synthesized as preproinsulin so it 
can pass to the endoplasmic reticulum (ER) where the signal sequence is proteolytically 
removed to form proinsulin. Proinsulin is a polypeptide that consists of the A, B, and C 
chains, in the order B-C-A, as depicted in Figure 2.1. The C chain is a peptide that connects 
the A and B peptides to promote proper folding and formation of A-B and intra-chain A 







Figure 2.1: Proinsulin hormone structure.  Illustration by [31]. 
 
 
From there, proinsulin follows a regulated secretory pathway (RSP) depicted and 
described in Figure 2.2. In brief, proinsulin gets shuttled via vesicles from the RER to the 
trans-golgi network (TGN) where the hormone aggregates are eventually packaged into 
clathrin-coated immature secretory granules for controlled release. Vesicles are also 
packaged with prohormone convertases PC1/3 and 2 for C-peptide cleavage to form active 
insulin within the granules. Insulin-containing, mature secretory granules are stored within 
the cell and fuse with the plasma membrane in response to extracellular glucose stimuli for 
insulin release. Constitutive vesicles, on the other hand, are immediately shuttled to the 
plasma membrane for fusion and release.  cells can control proinsulin synthesis rates at 
the transcriptional and translational levels [32], with insulin synthesis and release 








Figure 2.2: The general regulated secretory pathway (RSP). After synthesis, secretory 
peptides are packed into vesicles (red) derived from the ER membrane. These vesicles are 
directed to the most-trans cisternae of the Golgi complex. (2) Protein sorting receptors and 
ER-resident proteins mistakenly directed here are recycled back to the ER within vesicles 
(green). Once in the trans-golgi network (TGN), proteins are sorted in specific subdomains 
of this compartment. (3) Lysosomal hydrolytic enzymes are packed within clathrin-coated 
vesicles (blue) that are transported to and fuse with late endosomes. (4) Other TGN-derived 
clathrin-coated vesicles are loaded with secretory peptides (immature secretory granules), 
which undergo further processing and aggregation to form mature secretory granules. Upon 
extracellular stimulation, these granules fuse with the plasma membrane and release their 
content in a process referred to as regulated secretion. (5) Peptides packaged within 
uncoated vesicles are directed towards the cell surface in a constitutive manner 
(constitutive secretory pathway). (6) Alternatively, it has been proposed the existence of 
intermediate compartments in which regulated and constitutive secretion diverge based on 
the capacity of secretory proteins to sort by aggregation. In this case, constitutive secretory 
proteins would be packed within clathrin-coated vesicles in a process named as 




It was first demonstrated by Curry et al. that  cells secrete insulin in a biphasic 
manner [35]: stimulated (after a meal; postprandial) and basal (after the meal is absorbed; 
postabsorptive) phases. The first stimulated phase of insulin release, as depicted in Figure 
2.3, is characterized by a burst of insulin that occurs within 5-10 minutes after a glucose 
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load and is followed by the second basal phase of prolonged insulin release at elevated 




Figure 2.3: Biphasic insulin release from mouse islets subjected to 10 mM glucose.  
This figure was published in [36]. 
 
 
 Diabetes Treatment Options 
T2D patients who have sufficient  cell mass can control their condition with healthy 
eating and exercise. As  cell mass diminishes, however, patients may need oral 
medications and/or exogenous insulin to meet target blood glucose levels. On the other 
hand, exogenous insulin therapy is the only option for T1D patients as they cannot produce 
insulin endogenously and are therefore also referred to as insulin-dependent diabetes (IDD) 
patients. 
In 1993, The Diabetes Control and Complications Trial demonstrated that intensive 
insulin therapy improved glycemic regulation and dramatically reduced the frequency and 
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severity of complications in T1D patients [2]. Since then, novel recombinant human 
insulins have been developed commercially to better mimic the first and second phases of 
 cell secretion through the preparation of rapid and long-acting insulin formulations [37]. 
However, even with intensive therapy, the pharmacokinetics of this approach are limited; 
the best rapid-acting insulin takes approximately 30 minutes to peak in the blood after 
subcutaneous administration while a higher peak after just 5 minutes is observed after 
endogenous  cell secretion. Figure 2.4 is representative of the relative pharmacokinetic 
differences between various insulin formulations and endogenous secretion. 
Regardless of significant improvements in pharmacokinetics, insulin delivery via 
daily discrete needle injections or continuous subcutaneous insulin infusion (CSII) by 
pump [38] could never match the precise glucose-sensitive insulin release provided by  
cells working at all times. The current insulin therapy approach is therefore limited in its 
ability to tightly regulate blood glucose levels and intensive application merely delays 
rather than prevents morbidity and mortality in T1D patients. Al-Tabakha and Arida 
extensively reviewed the challenges of current (syringes, CSII, jet injectors, and pens) and 
future (inhalers, mouth sprays, pills, and patches) insulin delivery systems in which they 





Figure 2.4: Pharmacokinetics of various rapid and long-acting insulin formulations 
in the blood after subcutaneous injection compared to endogenous, or non-diabetic, 




 Cell-Based Insulin Therapy 
Using cells and encapsulated cells as therapeutic devices for insulin delivery is 
promising in providing tight and continuous physiologic blood glucose regulation as an 
alternative to the discrete, daily insulin injection or infusion therapies that are currently 
used. Such an approach would also minimize patient interaction and thus dramatically 
improve quality of life. The term cell-based therapy encompasses a broad area of research 
including whole pancreas or islet transplantation, engineeredcell lines, stem cell 
differentiation into -like cells, in vivo gene therapy, and genetic engineering of isolated 









2.4.1 Islet Transplantation and  Cell Lines 
2.4.1.1 Allogeneic Islet Transplantation 
Compared to whole pancreas transplantation, islet transplantation (Figure 2.6) is a 
less invasive procedure and results in a shorter hospital stay with lower morbidity [42, 43]. 
Both procedures are reserved only for patients with severe cases of T1D due to cadaveric 
islet donor shortage, graft failure in the long-term, and the need for lifelong 
immunosuppressive treatment. Immunosuppression drugs increase patient susceptibility to 
opportunistic infections and incidence of malignancy; adverse effects of these drugs toward 




Figure 2.6: Process of islet transplantation.  Islets are isolated and purified from a 




In 2000, the Edmonton Protocol was established with an improved 
immunosuppressive regimen [48] that resulted in an increase from 8 to 44% patients with 
insulin independence one year after transplantation [49]. However, 76% already required 
insulin again at two years and most returned to insulin dependence by the fifth year. Areas 
for improvement in allogeneic islet transplantation are outlined in [50] as enhancing the 
quantity and quality of the pre-transplant material and prolonging post-transplant graft 
survival. 
In an effort to improve the quantity and quality of pre-transplant material, 
researchers aim to improve the islet isolation procedure by making gentler enzyme 
cocktails that yield more intact islets, minimizing islet culture time pre-transplant, and 
optimizing purification methods [51]. On the side of improving post-transplant islet 
survival, researchers are either trying to come up with less toxic immunosuppressive 
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regimens [52] or enhance immune isolation technologies to obviate the need for 
immunosuppression drugs [53]. 
 
2.4.1.2 Xenogeneic Islet Transplantation 
In an effort to address the human islet supply issue, pig islets are being investigated 
as an unlimited, alternative cell source due to the close similarity in insulin and secretion 
kinetics between pig and human islets [54, 55]. To use this xenogeneic approach clinically 
requires encapsulation for partial immune protection [56] and has shown some promise in 
large animal models and humans, but the rate of insulin independence is highly variable 
and short-lasting [6-11]. There is also concern of the possibility of transmitting porcine 
endogenous retroviruses (PERVs) to humans after transplantation, which some studies 
have demonstrated as possible [57, 58] and others as impossible [59-61]. One of the 
suspected challenges to the success of this approach may be in evading the host 
inflammatory response after xenograft transplantation, as large animal and human studies 
have consistently reported fibrotic or inflammatory responses [6-11]. 
 
2.4.1.3  Cell Lines 
Insulinoma-derived  cell lines have been pursued to provide an ample supply of 
alternative donor cells due to their proliferative capacity and ability to maintain function at 
high passage numbers; an additional benefit is the ease with which  cell lines may be 
genetically engineered for effects such as improved function and survival [62]. However, 
in the past 30 years, generating and using human  cell lines have proven complicated [63-
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66]. Generation of the NAKT-15 human  cell line in 2005 appeared promising, but no 
reports of its utility have been published since then [67]. Only in the past couple of years 
has a new promising human  cell line named EndoC-bH1 been developed with potential 
as a tool for replacement cell therapy [68]. For these reasons, much of the literature consists 
of experimental studies on rodent  cell lines that have been successfully generated.  
Commonly used  cell lines for research are based on the mouse TC cell line that 
was originally derived from transgenic mice carrying a hybrid insulin-promoted simian 
virus 40 tumor antigen gene [69]. The early variant, TC-3, can process proinsulin and 
store insulin (20-30% of normal islets) similarly to normal  cells, but responds to 
subphysiological glucose ranges (0.15-16.7 mM glucose) and proliferates uncontrollably 
[70]. The genetically engineered variant, TC-tet, has more normal glucose responsiveness 
(0.5-16 mM glucose) [71] and a bacterial tetracycline operon regulatory system that can be 
triggered with tetracycline to inhibit cell proliferation [72]. Table 2.1 compares insulin 
secretion rates from the two TC cell line variants against mouse islets, in which the best 










Table 2.1: Comparison of insulin secretion rates from TC-3 insulinomas [73], TC-
tet cells [74], and mouse islets [75].  The range of insulin secretion rates per cell from 
mouse islets was approximated from graphical data in [75] and based on the assumption 




2.4.2 Stem and Progenitor Cells 
A number of studies have indicated that stem cells could be an alternative donor 
cell source for T1D treatment. This approach could allow for an autologous cell therapy 
and would eliminate donor cell scarcity and possibly immune rejection issues. 
Differentiation of human pluripotent stem cells to generate pancreatic progenitor cells has 
shown promise [76], but fully functional  cells have not yet been produced in vitro [77]. 
The major drawbacks of using embryonic stem cells (ESCs) to generate insulin-producing 
cells are that they are difficult to differentiate into only insulin-producing cells, there are 
ethical and religious issues to deal with, and ESC transplantation has led to teratoma 
formation [78, 79]. Other studies have reported that mesenchymal stem cells (MSCs) can 
be differentiated into insulin-producing cells [80, 81] and some have even shown efficacy 
in diabetic rodent models [82, 83]. The overall major challenges to a stem cell approach 
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are that stem cells are still not well understood, they can form teratomas, differentiated 
insulin-producing cells secrete very low levels of insulin, and only short-term graft survival 
in vivo has been attained [79]. In addition, there is a possibility that the stem-cell derived 
 cells will be recognized by T1D patients for autoimmune destruction. 
 
2.4.3 Non- Cells 
Like stem cells, non- cells can potentially serve as an autologous cell source to 
alleviate donor cell scarcity and immune rejection issues. Contrary to stem cells, the non-
 cell approach does not require extensive differentiation protocols and eliminates the risk 
of unintended differentiation post-transplant. Non- cells may also better avoid 
autoimmune destruction in T1D patients; a study by Lipes et al. showed that, unlike  cells, 
insulin-secreting non- cells in nonobese diabetic (NOD) mice were not targeted or 
destroyed by the immune system [84]. The overall goal of this approach is to engineer the 
patient’s own healthy, non- cells into meal or glucose-responsive insulin secretors for 
transplantation back into the patient. Many non- cell sources and genetic engineering 
strategies have been investigated, each with their own challenges and none so far with 
complete preclinical success. 
 
2.4.3.1 Gene Therapy Strategies 
The gene therapy method is an important consideration when engineering non- 
cells for sustained insulin expression over time. The two different strategies are ex vivo 
gene therapy in which cells are isolated from the patient to be genetically engineered and 
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transplanted back into the patient, and in vivo gene therapy which involves the genetic 
modification of cells as they reside in the patient. In either of these cases, there are two 
general gene delivery methods: viral and non-viral. The former is referred to as 
transduction and the latter as transfection. Viral transduction is generally the most efficient 
means of gene introduction, but carries with it some safety concerns. On the other hand, 
transfection is safer, but has been inefficient at transferring genes. 
 
Viral Transduction 
The most widely studied viruses for gene transfer systems are retrovirus, lentivirus, 
adenovirus, and adeno-associated virus (AAV). AAV and lentivirus have been successfully 
used to deliver the genes necessary to generate insulin-secreting hepatocytes and 
enteroendocrine cells [85-87]. AAVs are human parvoviruses that can transduce cells 
through both episomal transgene expression and random chromosomal integration for 
permanent expression [88]. Lentiviruses are RNA-viruses based on human 
immunodeficiency virus-1, non-human immunodeficiency, or feline immunodeficiency 
viruses. By integrating into the host genome, they could lead to long-lasting and stable 
transgene incorporation. Although gene silencing has been identified as a challenge in 
achieving long-lasting transgene expression after viral transduction [89-91], recent studies 
have shown that inhibiting histone deacetylases (HDACs) in virally transduced cells may 
reverse gene silencing and reactivate transgene expression [92-95]. HDAC inhibitors 






Transfection in mammalian cells with plasmids of naked DNA containing the gene 
of interest is another viable method for gene delivery, where selection via antibiotic 
resistance is normally performed in in vitro applications. This is an approach that has been 
used the most in engineering non- cells for insulin secretion [15, 16, 18, 96-100]. It has 
also received attention as a safer alternative to viral transduction for in vivo gene therapy. 
However, even if delivery is efficient, transfection in vivo is only transient which precludes 
its application in treating diseased states like diabetes in which sustained transgene 
expression is required [101]. 
 
2.4.3.2 Cell Sources 
The ideal non- cell candidate should be glucose or meal-responsive, express 
prohormone convertases PC1/3 and PC2 for proinsulin processing, and use a regulated 
secretory pathway (RSP) for quick hormone release. Proinsulin processing is important for 
both the secretion of active insulin as well as the cleavage product, C-peptide, which has 
shown to be beneficial in preventing hyperglycemia-induced vascular and neural 
dysfunction in animal and clinical diabetes models [102-105]. 
The first target non- cells to be studied were monkey kidney cell lines [106, 107], 
fibroblasts [108], and Chinese hamster ovary cells [109], all of which were transfected with 
the insulin gene. However, since these cells were unable to process proinsulin, they 
released biologically inactive insulin. Next, researchers showed that modifying the insulin 
gene for cleavage by the ubiquitous enzyme, furin, in NIH 3T3 fibroblasts, led to 
biologically active insulin secretion [110]. When applied to muscle in diabetic mice, basal 
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insulin levels were comparable to those observed from normal mice [111, 112]. This 
approach is limited, however, and only allows for basal secretion due to the lack of 




Neuroendocrine cells are appealing since they have an RSP and the enzymatic 
machinery required to process proinsulin. AtT20, a mouse corticotropic cell line derived 
from the anterior pituitary, has been engineered to express active insulin, but they lack 
glucose-responsiveness [84, 113-115]. Hughes and Motoyoshi et al. managed to engineer 
AtT20 cells for glucose-sensitivity via co-transfection with genes encoding the glucose 
transporter (GLUT2) and glucokinase, but stimulated insulin release was lower by more 
than 2-fold relative to release rates after stimulation with 8-bromo-cyclic AMP, a cAMP 
analog [97-99]. In 2003, Wu et al. demonstrated that engineered primary rat pituitary cells 
co-expressing human insulin and the GLP-1 receptor, co-secreted pituitary hormones and 
human insulin after oral glucose tolerance testing in mice [116]. The major limitation of 
this approach, however, is that over-secretion of adrenocorticotropic hormone as a result 
of glucose-sensitivity could severely disrupt the metabolic state of the patient. 
 
Liver Cells 
Hepatocytes have glucose-sensitive molecules such as GLUT2 and glucokinase, 
and several promoters that can be used for in vivo liver-targeted insulin gene therapy [117]. 
Lack of proper enzyme machinery, however, requires the introduction of a furin-cleavable 
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proinsulin gene [118]. Intraportal gene delivery of furin-cleavable insulin via adenovirus 
or AAV under the control of a liver-specific, glucose-responsive promoter resulted in 
nearly normal blood glucose levels in diabetic rats [119]. Lack of an RSP for glucose-
responsiveness can be addressed by making modifications to the promoter driving insulin 
transgene expression [120] and secretion kinetics can be improved through insulin mRNA 
destabilization [121] but regulation at only the transcriptional level still results in slower 
insulin dynamics compared to  cells [119].  
 
Intestinal Endocrine Cells 
Enteroendocrine cells are appealing as non- cell candidates due to their close 
similarity to  cells: post-prandial response system, insulin-processing proteases, and 
secretory granules for quick release [13, 122]. After a meal, enteroendocrine release of 
incretin hormones follows similar kinetics to insulin secretion from  cells (Figure 2.7). A 
subpopulation of enteroendocrine cells is K cells which are mainly located in the stomach, 
duodenum, and jejunum and they secrete gastric inhibitory peptide (GIP). Initial proof-of-
concept studies showed that mice transgenic for human insulin-secreting K cells were 
resistant to streptozotocin (STZ)-induced diabetes [12]. Similarly, insulin secreting 
enteroendocrine G cells significantly reduced mouse blood glucose levels [14]. The 
engineering of K cells isolated from the heterogeneous immortalized STC-1 cell line [15, 
16] and stable transfection with an insulin transgene, have permitted preclinical evaluation 
without resorting to transgenics. Insulin-secreting K cell clones were selected and tested 
for efficacy after cell transplantation into diabetic mice. Both studies reported restoration 
of normoglycemia, but mice became hypoglycemic as unrestricted cell proliferation 
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increased insulin production beyond therapeutic levels. In a K cell study that employed 
controlled cell growth methods, no effect was observed on blood glucose levels in diabetic 
mice until a drug-inducible element was incorporated into the insulin transgene [17]. 
Yet another subpopulation of enteroendocrine cells called L cells is located in the 
jejunum, ileum, and colon where they secrete glucagon-like peptide-1 (GLP-1) after a 
meal. GLP-1 plays an important role in potentiating glucose-mediated insulin secretion 
from  cells, in supporting  cell proliferation and regeneration, and in protecting  cells 
against apoptotic cell death [123, 124]. In 2003, Tang et al. transduced the heterogeneous 
human L cell line, NCI-H716, via recombinant AAV (rAAV)-mediated transfer of the 
human insulin transgene, after which 2% (wt/vol) meat hydrolysate (MH) simultaneously 
stimulated GLP-1 and insulin secretion in a similar manner and co-localization of both 
hormones were observed in secretory granules [125]. In 2008, Bara et al. used the GLUTag 
L cell line to stably transfect with the human B10 insulin transgene and generated the 
GLUTag-INS cell line [18].  
B10 human insulin differs from wild-type human insulin by a single amino acid 
residue on the B-chain due to a single point mutation in the proinsulin gene substituting 
aspartic acid for histidine. It has been shown to be 4-5 times greater in potency than that of 
the natural hormone and is called superactive insulin [126]. GLUTag cells are immortalized 
murine L cells which make up a homogeneous population with comparable function to 
primary L cell cultures and various in vivo models [127]. For this reason, GLUTag cells 
provide a useful model for L cell regulated secretion studies and they can serve as an 
allogeneic donor source for experimental studies in mice. Extensive studies of GLUTag-
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INS in vivo, however, showed that insulin secretion was likely insufficient in affecting 




Figure 2.7: Plasma insulin, GLP-1, and GIP responses to oral ingestion (arrows) of 





The highest reported range of secreted insulin from intestinal endocrine cells in 
vitro is only 5-22% of TC-3 cell line secretion [18, 73]. This may suggest that insulin 
transgene expression is low and better gene delivery techniques should be investigated. 
 
 Construct Technologies for a Tissue Engineered Pancreatic Substitute 
Contrary to a mechanical artificial pancreas, the bioartificial pancreas (BAP) is 
defined as a cell-based construct that can be easily transplanted with little or no 
immunosuppression, is capable of long-term blood glucose regulation, and is retrievable 
for biopsy or replacement if necessary [128]. The construct should serve as an immune 
isolation device to prevent rejection and eliminate the use of immunosuppression, and/or 
provide an optimal environment to support long-term cell function. The encapsulation 
material and device configuration are important considerations in fabricating a successful 
BAP for biocompatibility, immune protection, optimal cell loading density, and good 
diffusional capacity. Since the term BAP is often used to describe islet-containing devices, 
the more general tissue engineered pancreatic substitute (TEPS) terminology will be used 
herein and defined as a BAP that contains any of the previously outlined insulin-secreting 
cell types. 
 
2.5.1 Choice of Materials 
The material must serve as a semi-permeable membrane which physically separates 
the graft from host antibodies and immune cells, but also allows for the influx of glucose 
and nutrients, and the efflux of insulin and waste products. There are two very general 
categories that biomaterials fall into for cell encapsulation devices: rigid and flexible [21]. 
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Fairly rigid biomaterials with rough surfaces are often used to elicit a host response such 
as neovascularization at the transplant site for increased oxygen supply. Unfortunately, this 
also normally elicits an immune response followed by host cell adhesion and fibrotic 
overgrowth [129]. Such rigid devices are usually formed using synthetic polymer 
membranes like polytetrafluroethylene (PTFE), poly acrylic acid, polyethylene oxide, poly 
vinyl alcohol, polyphosphazene, and poly lactic and glycolic acids [130-132]. The latter 
two form synthetic hydrogels, but since they are designed to erode, are unappealing options 
for a long-lasting TEPS. 
Flexible biologic polymers with smooth surfaces can be the best at evading 
detection by the host immune system and the most popular materials are naturally occurring 
hydrogels like collagen, gelatin, hyaluronate, fibrin, alginate, agarose, and chitosan. The 
difficulty with using natural materials such as these is in achieving high purity and identity 
of starting materials, as is the case with alginates [133]. Alginates have low interfacial 
surface tension (reports range from 56-76 mN/m) which aids in the avoidance of host 
protein adsorption and cellular adhesion [134]. This and the in vivo stability of alginates to 
oxidative damage have attracted much attention to its use as a material for developing 
TEPS [21]. 
Alginates, derived from brown algae, are a family of unbranched anionic 
polysaccharides arranged in homo- or hetero-polymeric block structures of mannuronic 
(M) and guluronic (G) acid. Stiffness and flexibility of the material can be tuned by varying 
alginate composition. A high M:G ratio increases the elasticity and flexibility of the 
material compared to a low M:G ratio which increases the stiffness. The composition 
affects alginate viscosity and influences its mechanical stability, permeability, swelling 
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properties, and surface roughness. A potential limitation is the large-scale isolation and 
purification of alginates from natural sources. 
 
2.5.2 Device Configuration 
The purpose of encapsulation is to provide a physical barrier against host immune 
cell and antibody infiltration, and allow nutrient and oxygen influx as well as insulin and 
waste efflux. Unfortunately, small toxic molecules such as cytokines and nitric oxide can 
also pass through semi-permeable membranes such as these and damage encapsulated 
cells. Protection methods are being developed to address this issue and are discussed in 
Section 2.7: In Vivo Construct Integration. 
Three major approaches to encapsulation have been studied in developing a TEPS: 
intravascular macrocapsules, extravascular macrocapsules, and extravascular 
microcapsules (Figure 2.8). Macrocapsules provide one immune isolation barrier for all 
transplanted cells and are normally on the millimeter scale compared to micrometer sized 





Figure 2.8: The three major configurations for a tissue engineered pancreatic 
substitute, published in [135]. 
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Intravascular macrocapsule devices are implanted by vascular anastomoses into the 
host blood vessels for close contact between insulin-producing cells and blood, similar to 
islets in vivo. This was accomplished by fabricating a microporous tube or capillary 
bundles for blood flow through the lumen and cell attachment to the outer tube, similar to 
the intravascular diffusion chamber shown in Figure 2.9. The most extensively studied 
diffusion chamber was based on the one developed by Chick et al. [136] and was found to 
restore normoglycemia in diabetic rats [137], dogs [138], and monkeys [137]. However, 
the major problem was the occurrence of blood clotting as a result of insufficient material 
biocompatibility and small tube diameters. Modifications to device materials and tube 
diameters have reduced blood clotting, but only for a short time [139]. The intravascular 
macrocapsule configuration therefore receives less attention due to the major transplant 









A major advantage to using an extravascular rather than intravascular approach is 
that the risks are much lower since biocompatibility issues with the former normally affect 
the graft instead of the recipient. Additionally, multiple transplant sites such as the 
peritoneal cavity and subcutaneous site are available, simplifying the transplant and 
retrieval processes and better qualifying as a clinically acceptable TEPS. The macrocapsule 
geometry can vary from planar to tube-like, hollow-fibers (Figure 2.10) and can get as large 
as 3 cm by 8 cm [19]. Large devices like these, however, result in poor graft nutrition and 
oxygenation due to increased diffusional distances between the cells and the surrounding 
environment [140]. In addition, since islet viability is substantially reduced by increasing 
cell numbers, the loading density is kept quite low. Another disadvantage is that 
macrocapsules tend to break more easily in vivo due to physiological stress [41, 141, 142].  
A commercially available macrodevice containing islets, TheracyteTM, is 
comprised of a double membrane of PTFE where the inner selective membrane prevents 
immune cell contact with the graft and the outer, less selective membrane, facilitates 
angiogenesis (Figure 2.10D). Preclinical studies, however, have shown poor results using 






Figure 2.10: Extravascular macrocapsules. Algire and Millipore diffusion chambers 
with cell-containing membranes in the middle or outside of plastic rings, illustration by 
[145]. B) Agarose disc construct containing insulin-producing cells encased in cell-free 
agarose, taken from [41]. C) General schematic for a tube-like macrocapsule device, 
illustration taken from http://www.isletmedical.com/pages/company_competition, D) 
TheracyteTM device, illustration from [135]. 
 
 
Microencapsulation involves the formation of a spherical semi-permeable 
membrane around therapeutic cells (Schematic 2.1). One of the main advantages of the 
microcapsule configuration is its high surface area to volume ratio, allowing for better 
diffusion capacity and higher cell loading density relative to a macrocapsule device. Small 
microcapsule diameters ranging from 150-700 m are fabricated for optimal oxygen 
diffusion to prevent cell necrosis, particularly in the case of islets [140, 146]. Out of the 
three encapsulation approaches mentioned, the microcapsule configuration presents the 
easiest and least invasive surgical procedure for transplantation since just one simple 
injection is required. The downside, however, is that full graft retrieval is not possible but 
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may be necessary in the case of a host inflammatory response. As far as materials, 
hydrogels are preferred for cell microencapsulation because the procedure for fabrication 





Schematic 2.1: A microcapsule with a semi-permeable membrane surrounding 
insulin-secreting single cells for protection against host cells and antibodies. 
 
 
Alginate microcapsules are popular because their fabrication techniques have 
consistently shown preservation of cell function. A common technique is to use an 
electrostatic droplet generator in which cells mixed with alginate are passed through a 
needle to form droplets charged with high static voltage that fall into a collecting vessel 
containing a cross-linking solution with opposing polarity for gelation (Schematic 2.2). 
The size of the microcapsules can be varied by changing the needle height, voltage 





Schematic 2.2: An electrostatic droplet generator, illustration published in [148]. 
 
 
The most commonly studied ionic cross-linking solutions are calcium chloride and 
barium chloride. Duvivier-Kali et al. reported that microcapsules fabricated with 3.3% 
(wt/vol) sodium alginate characterized by high mannuronic acid and cross-linked in barium 
chloride solution yielded better biocompatibility and mechanical stability in rodent models 
(STZ-diabetic BALB/c and nonobese diabetic (NOD) mice) compared to those of low 
mannuronic acid cross-linked in calcium chloride solution [149]. Additionally, Safley et 
al. showed better biocompatibility and prolonged survival of porcine islets encapsulated in 
barium alginate in NOD mice [150] compared to the commonly employed alginate-poly-
L-lysine-alginate (APA) microcapsule configuration [151]. Transplanting islets or  cells 
encapsulated in barium alginate in this way has also been successful in restoring 
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normoglycemia in diabetic rodent models [149, 152, 153]. There is some concern, 
however, that the release of barium ions from transplanted microcapsules may cause 
toxicity [154], but more studies need to be performed to confirm this. 
 
 Preclinical Diabetes Models 
Choosing the best preclinical animal disease model for studying new therapies is 
important in determining the translatability of the approach to humans. For this reason, the 
animal model should reflect the human disease well. There are three general preclinical 
T1D models that are often used to evaluate a TEPS in vivo: the streptozotocin (STZ)-
induced diabetes model, pancreatomized models, and spontaneous diabetes models 
induced by an autoimmune response. The first and third methods will be covered here since 
pancreatomized models are less common. 
STZ, an N-nitroso derivative of glucosamine, was discovered in 1963 as a convenient 
drug for inducing diabetes [155]. STZ is a toxic glucose analogue that preferentially 
accumulates in  cells via the GLUT2 glucose transporter, leading to DNA fragmentation 
and  cell destruction [156]. The STZ-induced diabetes model can be applied to any 
experimental animal, most commonly mice, rats, pigs, and monkeys. The administered 
dose of STZ depends on the animal species and strain. Mouse strains used for this model 
are normally BALB/c or C57BL/6 with different optimal doses for each [157]. Researchers 
have the choice of administering a single high STZ dose or multiple smaller STZ doses to 
induce diabetes. The former is often chosen for convenience in rodent models, but can be 
unstable in terms of the diabetic condition and result in approximately 10-20% death. The 
latter method can achieve hyperglycemia with no, or few, animal deaths [158] and is 
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considered superior to the single injection model. In small rodent models, STZ is usually 
administered intraperitoneally (i.p.) because it is easier to manage than an intravenous (i.v.) 
injection. In the case of larger animals, however, i.v. may be preferable because a lower 
STZ dose can be used. The STZ-induced diabetes model is useful in testing therapeutic 
efficacy of a TEPS in terms of sufficient insulin production for normoglycemic restoration, 
but the effects of a T1D-like autoimmune response cannot be evaluated. 
 There are two models that come the closest to mimicking T1D etiology: the 
nonobese diabetic (NOD) mouse and biobreeding rat established by [159] and [160], 
respectively. These rodent models spontaneously become diabetic due to an autoimmune 
attack by T cells, B cells, macrophages, and natural killer cells, leading to insulitis and islet 
loss. These models are used to better understand the mechanism of T1D and to evaluate 
autoimmune effects on a promising TEPS. However, NOD mice also have inflammation 
of the thyroid, submandibular glands, and lacrimal glands which increases the complexity 
of the model. It is therefore important to first identify the research objective and then 
choose the most appropriate preclinical animal model to achieve valuable results. 
 
  In Vivo Construct Integration 
Once a TEPS shows promise in vitro, the next step is to evaluate its in vivo potential 
in a carefully chosen diabetes animal model. Some key considerations when transplanting 
a TEPS are what surgical method will be employed and where the TEPS is to be 
transplanted. A common transplant procedure for microencapsulated cells is to simply 
inject the microcapsules into the peritoneal cavity, but this may not always be the optimal 
site. The peritoneal cavity is limited by low oxygenation, limited capacity for 
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revascularization, and delayed glucose-responsiveness due to the large diffusional 
distances between the graft and blood vessels [161]. However, the reason for its appeal is 
that it can hold large volumes and thus allows for high transplanted cell numbers. This 
becomes important when donor cells secrete low levels of insulin per cell. Ideally, one 
would choose a site with vascular density for facilitated interchange of nutrients, oxygen, 
and insulin between the graft and the blood. In addition, that site should provide a less 
inflammatory microenvironment. Other clinically relevant (intramuscular, subcutaneous, 
omentum, and venous sac) and immuno-privileged (lymph node and anterior chamber of 
the eye) transplant sites are discussed in [161]. 
A major challenge to successful TEPS integration is developing a biocompatible 
construct that causes little or no host inflammatory response upon transplantation. Even 
with pure, flexible, and smooth alginate microcapsules, donor cells can shed antigens that 
diffuse out of the semi-permeable membrane and activate macrophages that cause the 
release of cytokines, nitric oxide, and oxygen radicals that destroy the donor cells [152, 
162]. For this reason, some researchers are investigating ways to tether bioactive agents to 
the construct that protect transplanted cells from inflammation. For example, one group 
showed improved protection of encapsulated islets exposed to pro-inflammatory cytokines 
by functionalizing hydrogels with the anti-inflammatory peptide, interleukin-1 (IL-1) 
[163]. 
Another important factor to consider is the diffusional distance between the graft and 
the blood supply in vivo. One of the prime reasons for failure of cell-based constructs is 
insufficient oxygen tension leading to cell death. Since this issue is observed in most 
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transplant sites, researchers are working on engineering ways to provide oxygen either by 
in situ oxygen generation or revascularization guidance [161]. 
Although these are likely limitations, the major obstacle in developing an optimal 
TEPS is the lack of understanding regarding graft behavior in vivo. The in vivo environment 
is essentially a black box in which the construct resides and only indirect and endpoint 
measurements are made to evaluate progress. These measurements give no indication of 
the time-scale to failure, thus limiting the ability for researchers to delineate critical factors 
that contribute to graft failure. An appropriate imaging technology should therefore be 
employed for minimally invasive, real-time graft tracking in vivo. Real-time imaging, 
alongside end physiologic measurements, can lead to the identification of key factors for 
construct failure and accelerate the development of a successful TEPS. 
 
 Imaging Technologies 
Biomedical imaging is critical to the development of optimal TEPS technologies 
because it allows researchers to gather physical and physiological information about the 
engineered tissue in vivo without disturbing or damaging the graft. This information is able 
to be gathered in real-time rather than after important events have caused graft failure, as 
is the case when measuring indirect effects like blood glucose and C-peptide levels. 
Imaging technologies are therefore important in the prediction and possible prevention of 
construct failure. Optical imaging, radiation based imaging, ultrasound, infrared imaging, 
and nuclear magnetic resonance (NMR) methods are described extensively in [164]. Here, 
only optical imaging and NMR methods will be discussed, as they are the most prevalent 
in the research and development of TEPS. 
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2.8.1 Optical Imaging 
Using an optical technique involves the measurement and imaging of visible light 
emitted from the graft. This can occur either as the result of an enzymatically catalyzed 
chemical reaction or in response to an excitation wavelength. An example of the former is 
the firefly luciferase enzyme which catalyzes the oxygenation of the substrate luciferin 
using ATP and oxygen to yield oxyluciferin and a photon. The photon emission from this 
reaction can be measured using a charge-coupled device camera. When the luciferase 
reporter gene is successfully incorporated into the cells of interest, the measured photon 
flux is proportional to the number of living cells, allowing for the quantitative tracking of 
cell mass and survival. Bioluminescence imaging (BLI) is a popular method for direct 
monitoring of cell fate in animals due to its low cost, high sensitivity, ease of operation, 
near background-free imaging conditions, and reduction of inter-animal variability [165, 
166]. The downside of this approach is that it is normally only applied to small animal 
models due to a short penetration depth (the signal is attenuated 10-fold for every 
centimeter of tissue depth). 
The first proof-of-concept BLI study with free islets offered encouraging results, as 
it demonstrated that islets transduced in vitro with a luciferase lentivirus could be 
quantitatively monitored long-term after transplantation in the kidney capsule of diabetic 
mice [167]. Subsequent studies investigated the use of BLI in early detection of islet graft 
rejection [168], islet survival immediately post-transplantation [169], and guided timing 
for corrective interventions [170]. Just a few studies have reported the use of BLI for 
tracking cell constructs [171-173], and only one for tracking a TEPS [174]. BLI 
incorporation could be an easy and inexpensive way to track a TEPS in diabetic rodents, 
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but more research needs to be done to investigate the advantages and limitations of this 
approach. 
Fluorescence is another popular optical imaging method, but the mechanism for 
emission is different. Instead of a chemical reaction, an excitation wavelength of 400-600 
nm is required for photon absorption by the fluorescence reporter protein which triggers an 
emission wavelength of 450-650 nm that can be measured. Tissues or cells can be tagged 
in a variety of ways like incorporating fluorescent reporter genes, using dyes, microspheres, 
or nanoparticles. The downsides of this approach are the short penetration depth, 
autofluorescence emitted from natural tissues, and high protein stability which precludes 
its use in tracking dynamic cellular processes. Protein degradation rates can be increased 
to address the latter issue, but this requires genetic manipulation [175]. For these reasons, 
BLI incorporation has become a more popular optical technique for in vivo cell tracking 
technologies. 
 
2.8.2 Nuclear Magnetic Resonance 
NMR techniques like Magnetic Resonance Imaging (MRI) and spectroscopic 
methods are frequently used in a variety of applications, both preclinically and clinically. 
MRI has been identified as a suitable tracking method for in vivo graft monitoring [176, 
177], with its own advantages and limitations [178]. Some studies have investigated the 
application of 19F NMR spectroscopy to measure the oxygen concentration at the graft site 
in mice post-transplantation of microencapsulated  cells [179, 180]. This method, 
however, only allowed for indirect graft monitoring. Alternatively, 1H NMR has been 
applied for direct monitoring of encapsulated  cells, but the macrocapsule construct design 
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that allowed for such monitoring was not optimal for cell function [181]. To preserve 
construct design, perfluorocarbons (PFCs) can be used as imaging contrast agents for 
computed tomography, ultrasonography, and MRI [182]. However, this only allows for 
spatial tracking of the capsules rather than the monitoring of living cell mass within the 
microcapsules. Ideally, the monitoring method should allow for minimally-invasive in vivo 




Previous work in our lab reports on the promise of using engineered, insulin-
secreting intestinal L-cells as a non- cell source to circumvent donor cell availability and 
autoimmune rejection issues associated with islet transplantation [18-20, 87, 125]. A major 
challenge in the field, however, has been in engineering cells with sufficient insulin 
secretion to lower blood glucose levels in preclinical diabetes animal models. In 
CHAPTER 3 of this thesis, a novel secretion enhancement method was applied to the 
GLUTag-INS cells previously developed in our lab to generate engineered L cells that 
significantly surpass reported insulin secretion from other enteroendocrine cells in the 
literature. 
Preclinical efficacy studies of engineered enteroendocrine cells are primarily 
studied as uncontrollable growth systems that lead to tumor formation [15, 16]. 
Encapsulation is a strategy for controlling cell growth, but has precluded therapeutic 
efficacy, perhaps partially due to suboptimal construct design. As reported in CHAPTER 
4 of this thesis, a barium alginate microcapsule configuration was investigated as an 
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appropriate construct design to allow for controlled cell growth, retained insulin secretion, 
and high cell loading densities. Compared to the previous macrodevice developed in the 
lab, the microcapsule configuration enabled insulin secretion rates that were 100-fold 
higher per graft volume. 
In most cases, graft efficacy is assessed by endpoint measurements from the animal 
model, but this has offered limited information into what happens to the graft within a 
clinically relevant timescale. In CHAPTERs 4 and 5, application and characterization of 
bioluminescence in vitro and in vivo are reported. This was the first study to show that 
injectable, free-floating microencapsulated cells could be tracked in real-time using 
bioluminescence imaging. 
Preclinical reports of transplanted controlled-growth systems containing insulin-
secreting enteroendocrine cells have been unable to show a lowering effect of blood 
glucose levels in diabetic rodents [17, 20]. CHAPTER 5 reports the therapeutic efficacy of 
the improved TEPS design containing the enhanced recombinant intestinal L cells. This 
study was the first to find a beneficial effect of such a construct on blood glucose levels in 
STZ-induced diabetic mice, but significant challenges remain to be addressed in an effort 




CHAPTER 3: NOVEL METHODS FOR INSULIN SECRETION 
ENHANCEMENT FROM RECOMBINANT L-CELLS 
 
 Abstract 
Genetically engineering intestinal endocrine cells for recombinant insulin secretion 
constitutes a promising cell-based approach for insulin dependent diabetes therapy. 
Generating cells with sufficient insulin secretion using conventional gene delivery 
methods, however, has proven challenging. In this work, we applied two enhancement 
methods to an already engineered L cell line with insulin secretion capabilities named 
GLUTag-INS. The first method, lentiviral transduction, increased insulin mRNA and 
secretion by 10- and 2-fold, respectively. After several passages, enhanced secretion was 
lost but cells still retained 3.5 times more insulin mRNA. Therefore, in itself, additional 
transgene incorporation was insufficient in generating therapeutic, insulin-secreting L 
cells. The second method, histone deacetylase inhibition (HDACi) with Trichostatin A, 
significantly revived transgene mRNA production and concurrently enhanced downstream 
steps in the regulated secretory pathway (RSP). With these methods combined, 
recombinant basal and stimulated insulin secretion rates of 655 and 888 fmol/(106 cells·h), 
respectively, significantly surpassed reported secretion from previously engineered 
intestinal endocrine cells by over 6-fold. In addition, some HDACi enhancement effects in 
engineered cells were able to be sustained for as long as seven days within a 3D, alginate 
microcapsule configuration. We concluded that therapeutic insulin production from L cells 
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(384 and 3930 fmol/(106 cells·h) for basal and stimulated, respectively) may be attainable 
by both increasing transgene incorporation and RSP efficiency. Furthermore, HDACi 
treatment is promising as a novel approach for enhancing graft secretion function from 
cells with an RSP, such as  and L cells. The findings from this study have allowed us to 
isolate promising research avenues in an attempt to accelerate the development of a non- 
cell-based diabetes therapy with real clinical potential. 
 
 Introduction 
Daily insulin injections and infusion by a pump are the current treatment options 
for insulin dependent diabetes (IDD) patients, neither of which are continuously regulating, 
closed-loop systems. As a result, the patient’s glycemic state is difficult to control and often 
leads to long-term complications like heart disease and stroke, hypertension, blindness, 
kidney disease, nervous system disease, and amputations [1]. Cell-based options like 
pancreas or islet transplantation are clinically used, but only for extreme, brittle cases of 
diabetes due to donor cell scarcity and adverse effects of immunosuppression treatment 
[183]. An alternative cell-based therapy approach is being explored with the overall goal 
of genetically engineering autologous non- cells for insulin secretion to fulfill donor cell 
demand and avoid autoimmune destruction [184]. 
Many non- cell sources and genetic engineering strategies have been investigated, 
each with their own challenges and none so far with complete preclinical success. The ideal 
non- cell candidate should be glucose or meal-responsive, express prohormone 
convertases PC1/3 and PC2 for proinsulin processing, and use a regulated secretory 
pathway (RSP) for quick hormone release. Muscle [96, 112, 185], skin [186, 187], and 
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fibroblast [76, 110] cells have been engineered for constitutive insulin secretion, but do not 
naturally process proinsulin and require modification of the insulin gene for cleavage by 
the ubiquitous enzyme, furin, to produce biologically active insulin [110]. This approach 
is further limited since these cells do not possess nutrient-responsive elements nor do they 
have an RSP.  
Pituitary cells can process proinsulin and have an RSP, but do not naturally respond 
to nutrients. Sambanis et al. showed that insulin secretion rates from engineered AtT20 
pituitary cells [114] were induced 6-fold after stimulation with 8-bromo-cyclic AMP 
(BrcAMP), a cAMP analog [113]. Hughes and Motoyoshi et al. managed to engineer 
AtT20 cells for glucose-sensitivity via co-transfection with genes encoding the glucose 
transporter (GLUT2) and glucokinase, but insulin secretion induction was more than 2-
fold lower than that observed from secretion stimulated by BrcAMP [97-99].  
Hepatocytes express glucose-sensitive molecules GLUT2 and glucokinase, but 
have no RSP and cannot process proinsulin [117]. Delivery of plasmids containing partially 
bioactive insulin transgenes for simple cleavage by furin in hepatocytes has improved 
glycemia in preclinical diabetes models [118]. Furthermore, intraportal insulin gene 
delivery via adenovirus or adeno-associated virus (AAV) under the control of a liver-
specific, glucose-responsive promoter [120] resulted in nearly normal blood glucose levels 
in diabetic rats [119]. However, recombinant hepatocytes, due to the secretion lag time 
resulting from transcriptional regulation, are unable to match the tight glucose regulation 
achieved by  cells after an intraperitoneal glucose load [119]. 
Enteroendocrine cells may be the best non -cell candidates due to their nutrient-
responsiveness, proinsulin processing abilities, and use of an RSP for fast hormone release 
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[13, 122]. Proof-of-concept studies in mice transgenic for insulin-secreting gastric G or gut 
K cells have shown promise in this approach [14, 122], but engineering intestinal endocrine 
cell lines for sufficient insulin secretion has proven challenging. The highest reported range 
of secreted insulin from intestinal endocrine cells is only 5-22% of the  cell line, TC-3 
(384-3930 fmol·106 cells-1·h-1) [18, 73]. TC-3 secretion is used here as the standard for 
comparison because a reasonable cell number (3-4x107 cells) could be transplanted to 
achieve a secretion output comparable to that from TC-tet cell grafts that restored 
normoglycemia in diabetic mice (19-92 pmol·h-1) [74, 180]. 
In two preclinical studies, blood glucose was reduced after transplanting engineered 
K cells, but uncontrollable cell growth and tumor formation likely contributed to this 
success by providing excessive amounts of insulin which eventually led to severe 
hypoglycemia [15, 16]. On the other hand, controlled growth preclinical studies that 
eliminated the chance of tumor formation have failed so far in achieving normoglycemia 
[17, 20]. Engineering a cell line to produce therapeutic quantities of recombinant insulin is 
therefore needed to transplant reasonable cell numbers under controlled growth conditions 
for a safe cell-based insulin therapy. 
Up to now, the focus of engineering enteroendocrine cell lines for insulin 
expression has been primarily on genetic incorporation using various viral or non-viral 
gene delivery systems. These, however, have led to inadequate insulin secretion. Little 
emphasis has been placed on gene expression enhancement or targeting other steps 
downstream of transcription in the RSP and novel methods should be developed along this 
line to enhance secretion. Without a better understanding of the RSP in enteroendocrine 
cells, however, it is difficult to target the right mechanisms for improved secretion. For 
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these reasons, it is necessary to also identify potential limiting steps that can be targeted to 
improve the enteroendocrine RSP for insulin production. 
Some recent findings have shown that treating islet or  cell lines with the histone 
deacetylase inhibitors (HDACi) Valproic Acid (VPA) or Trichostatin A (TSA), caused an 
increase in insulin secretion output [188, 189]. In another study, TSA was shown to 
increase Brain-Derived Neurotrophic Factor (BDNF) release from neuronal cells by acting 
on HDAC6 and increasing acetylated tubulin levels which increased vesicular transport 
[190]. In this work, TSA was used as a tool to better understand recombinant insulin 
production and secretion from intestinal L cells by evaluating its effects on insulin mRNA 
levels and various steps of the RSP. In addition, the longer-term effects of a one-time TSA 
treatment were evaluated to investigate its use as a novel method for hormone secretion 
augmentation. 
Our lab previously engineered the murine GLUTag L cell line for insulin secretion 
by stable transfection with a vector containing the B10 human insulin gene and neomycin 
resistance [18]. The highest secreting clones were selected and used thereafter as the 
GLUTag-INS cell line and these have remained one of the highest reported insulin-
secreting enteroendocrine cells. Although GLUTag-INS had a higher insulin secretory 
capacity (86-180 fmol·106 cells-1·h-1) than Zhang et al.’s normoglycemia-achieving K cells 
(32-70 fmol·106 cells-1·h-1) [16], transplanting GLUTag-INS within a controlled-growth 
system had no effect on blood glucose levels in streptozotocin (STZ)-induced diabetic mice 
[20]. Human insulin, however, was detected in the blood of treated mice. 
The overall objective of this work was to improve secretion from the GLUTag-INS 
cell line and identify promising research avenues for closing the gap between insulin 
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secretion from recombinant L cells and endogenous  cells. Here we report the short- and 
long-term effects of two novel enhancement methods involving additional insulin 
transgene incorporation and TSA treatment. Limiting steps within the RSP of the 
engineered L cell lines, possible targets for enhancement, and the broad application of a 
novel HDACi treatment for hormone secretion augmentation are discussed. 
 
 Materials and Methods 
3.3.1 Cell Culture 
GLUTag-INS and further genetically engineered GLUTag-INS cells were cultured 
as in [191] using Dulbecco’s modified Eagle’s medium (DMEM) with 25 mM glucose, 
without L-glutamine (Corning cellgro, Manassas, VA, Cat. #15-017), and supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. Cultures were propagated in 
a humidified incubator at 37oC/5% CO2. 
 
3.3.2 Secretion Enhancement via Lentivirus Transduction 
The enhanced, GLUTag-eINS cell line, was generated by transducing GLUTag-
INS at passages 15-17 with the wild-type human insulin lentivirus (LV-WT-INS; Emory 
University; Dr. John Shires). The lentiviral vector, as shown in Schematic 3.1, contained 
the wild-type human insulin gene driven by a cytomegalovirus (CMV) promoter for 
constitutive gene expression. The Internal Ribosomal Entry Site (IRES), positioned 
between the human insulin and green fluorescence protein (GFP) reporter genes, provided 
an additional site for ribosomal binding during translation so that human insulin and GFP 
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proteins could be separately synthesized. Two days after seeding in 12-well plates at 1x105 
cells/cm2, lentivirus was added at a multiplicity of infection of 30 to fresh medium 
containing 8 g/mL of polybrene (Sigma, St. Louis, MO). After 24 hours, the medium in 
wells was changed to fresh, cells were expanded and passaged twice, and insulin secretion 




Schematic 3.1: Lentiviral vector containing the wild-type human insulin gene driven 
by a CMV promoter for constitutive expression followed by the GFP reporter gene.  




3.3.3 Fluorescence Activated Cell Sorting 
Since only transduced cells expressed GFP, fluorescence served as an indicator of 
transduction efficiency measured by fluorescence activated cell sorting (FACS). FACS 
was also performed on GLUTag-eINS cells to generate a pure, GFP-positive population. 
Using the BD FACS Aria cell sorter (BD Biosciences; San Jose, CA), GFP-positive and 
GFP-negative cells were sorted into separate tubes and percentages of each were estimated 
by FACSDiva software after 10,000 events. The negative control, non-transduced 
GLUTag-INS cells, was used to set the fluorescence threshold under which cells were 
sorted as GFP-negative and above which cells were sorted as GFP-positive. This threshold 
was determined for each experiment and representative images of the setup and software 
analyses are shown in Figure 3.1. The GFP-positive population of GLUTag-eINS cells was 
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collected and seeded as a monolayer culture in 12-well plates for expansion, passaging, 
and ISR testing. After three passages, cells were conventionally frozen as the new cell line, 
GLUTag-EINS (EINS). Post-thaw, ISR tests and relative insulin mRNA quantitation were 




Figure 3.1: Representative setup and analysis screen using FACSDiva software for 
GFP cell sorting.  P1 is the total sorted population of GLUTag-eINS cells, P2 is the GFP-
positive population, and NOT(P2) is the GFP-negative population. A) Frequency plot of 
detected fluorescence from non-transduced GLUTag-INS cells, the negative control. B) 
Frequency plot shown during cell sorting in which GFP-negative cells below the set 
threshold were sent to one tube and GFP-positive cells above the set threshold were sent to 
a different tube. C) Population statistics chart indicating the percentages of each sorted 
population out of 10,000 sorted cells. 
 
 
3.3.4 Human Insulin mRNA Quantitation 
Cells were harvested for RNA isolation using the E.Z.N.A Total RNA Kit I 
(OMEGA bio-tek, Norcross, GA) followed by cDNA synthesis using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY). cDNA was 
synthesized from 1g of RNA following manufacturer’s protocols. Real-time, relative 
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quantitation of insulin mRNA was accomplished using the SYBR Select Master Mix 
(Applied Biosystems) and the StepOnePlus Real-Time PCR System (Life Technologies) 
for measurement and comparative CT method analysis. Human insulin primers were 
designed using National Center for Biotechnology Information’s (NCBI’s) Primer-BLAST 
design software and mouse beta-actin (ACTB) primers were used as endogenous controls. 
Primer sequences were as follows: forward human insulin 5’-CTA CCT AGT GTG CGG 
GGA AC-3’, reverse human insulin 5’-AGC TGG TAG AGG GAG CAG AT-3’, forward 
mouse ACTB 5’-GCA CAG CTT CTT TGC AGC TC-3’, reverse mouse ACTB 5’-CTT 
TGC ACA TGC CGG AGC C-3’. All primers were used at 300 nM concentrations. 
 
3.3.5 Secretion Enhancement via Histone Deacetylase Inhibition 
A dose-response curve was constructed to determine the effect of varying TSA 
concentrations on insulin secretion and viable cell numbers. This study was performed on 
GLUTag-INS cells to determine an optimal TSA concentration for the remainder of the 
study, assuming GLUTag-INS and EINS trends were similar. Serial dilutions of TSA were 
made in dimethyl sulfoxide (DMSO; Sigma) starting at 2500 nM (six concentrations were 
tested: 0 nM, 156 nM, 313 nM, 625 nM, 1250 nM, and 2500 nM). After a 24 hour 
incubation at these varying TSA concentrations, cells in wells were washed twice in 
Dulbecco’s Phosphate-Buffered Solution (DPBS; Corning cellgro) containing calcium and 
magnesium and then changed to 5mM glucose basal medium for a two hour incubation 
period, at which point samples were collected for insulin measurement. After collecting 




For short-term studies, GLUTag-INS or EINS cells were seeded in 12-well plates 
at densities of 1.3x105 cells/cm2 two days before TSA treatment. On day 0 of the 
experiment, culture medium was changed to fresh in each well and TSA was added to a 
final concentration of 625 nM or 0 nM, the latter serving as the non-treated control group 
for direct comparison. After 24 hours of incubation, cells were washed twice with DPBS. 
ISR tests were then performed and cells in parallel wells were incubated for one hour in 5 
mM glucose basal medium to be harvested for intracellular insulin and total RNA 
collection. To collect intracellular proteins, TSA and non-treated cell pellets were lysed 
using the Mammalian Cell Lysis Kit (Sigma). Proinsulin and insulin concentrations were 
then measured from the same secreted or intracellular sample by ultra-sensitive human 
insulin and human proinsulin radioimmunoassays (RIA; Millipore, Billerica, MA). 
 
3.3.6 Long-Term Effects of a 24h TSA Treatment 
Long-term effects of TSA were evaluated in microencapsulated EINS cells for 14 
days in culture. EINS cells were grown in T-75 tissue culture treated flasks to 
approximately 90% confluency and treated for 24 hours with TSA at a 625 nM 
concentration. Cells were then washed twice with DPBS, trypsinized, microencapsulated 
in LVM alginate (LVM; Novamatrix, Drammen, Norway), and cross-linked in 30 mM 
BaCl2 solution using an electrostatic droplet generator (Nisco Engineering, Zurich, 
Switzerland) as previously described [180]. ISR tests were performed on 0.1 mL 
microcapsule volumes 1, 7, and 14 days after microencapsulation. Microcapsules were also 
solubilized in ethylenediaminetetraacetic acid disodium salt dihydrate solution (ED2SS; 
0.2 M; pH 9) to harvest cells for intracellular protein collection and total RNA isolation. 
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3.3.7 Insulin Secretion Rate Test 
ISR tests performed on cell monolayers and microencapsulated cells involved 
subjecting cells to basal conditions (DMEM with 5mM glucose) for two hours followed by 
a two hour step-up period under stimulating conditions (DMEM with 5 mM glucose and 
2% meat hydrolysate (MH); Sigma). Media samples were taken at 0 and 2 hours (t0, t2-) 
after adding basal medium and 0 and 2 hours (t2+, t4) after changing to stimulating medium 
(Schematic 3.2). To normalize secretion rate data to viable cell numbers, monolayers were 
trypsinized after ISR tests and trypan blue viable cell counting was performed using a 
hemacytometer. Secretion data from microcapsules were normalized to metabolic activity 
measured by alamarBlueTM (Life Technologies, Grand Island, NY) as in [192] using a one 
hour incubation period. Metabolic activity was used as a measure of viable 
microencapsulated cell number because, over time, cell remodeling and aggregation in 




Schematic 3.2: ISR tests involved two hour incubation periods in basal and 








3.4.1 Secretion Enhancement via Lentiviral Transduction 
GLUTag-INS cells were transduced with LV-WT-INS and passaged twice, 
resulting in a 3-fold enhancement in both basal and stimulated insulin secretion rates 
(Figure 3.2A). A 61% transduction efficiency was achieved and FACS led to a 97% pure 
EINS population. EINS cells were then passaged three times and conventionally frozen. At 
early passages post-thaw (p<8), EINS produced 10-fold more insulin mRNA than 
GLUTag-INS, but secretion was only 2-fold higher (Figure 3.2). Then after several 
passages (p>7), EINS produced 3.5 times more insulin mRNA than GLUTag-INS, but 
secretion was no longer higher. While there was a general trend of decline, possibly due to 
gene silencing, in both insulin mRNA and secretion over passaging, fold-increases in EINS 
secretion responded disproportionately to changes in insulin mRNA. Additionally, higher 
mRNA production did not necessarily lead to more secretion. This implies that one or more 














Figure 3.2: Long-term stability of human insulin mRNA and secretion after lentiviral 
transduction of GLUTag-INS.  A) After transduction, eINS were passaged twice and 
purified to a 97% GFP-positive population to be conventionally frozen as the EINS cell 
line after three passages. ISR tests were performed on non-transduced GLUTag-INS (n=6), 
eINS passaged twice (n=3), EINS passaged three times (n=3), EINS at low passage 
numbers 4-7 post-thaw (n=7), and EINS at high passage numbers 8-11 post-thaw (n=6). 
From left to right, the average stimulation indices (SIs) ± standard error were 2.5 ± 0.2, 2.5 
± 0.3, 2.4 ± 0.1, 2.0 ± 0.1, and 1.8 ± 0.1. SIs were determined by dividing stimulated by 
basal secretion. B) Human insulin mRNA levels from early and late passages of EINS post-
thaw were quantified relative to GLUTag-INS. Asterisks indicate a statistical difference 
from GLUTag-INS either under basal or stimulated conditions in graph A, or GLUTag-






3.4.2 Short-Term HDACi Studies 
The dose-response curve in Figure 3.3 depicts the effects of varying TSA 
concentrations on the secretion and viable number of GLUTag-INS cells. TSA treatment 
resulted in significant cell death dependent on dose. However, TSA had an enhancing effect 
on insulin secretion per viable cell, with an initial 2 to 2.4-fold increase at low TSA 
concentrations (0.157-0.625 M) increasing to 3.5 times higher than non-treated cells at 
concentrations of 1.25-2.5 M. Based on these data, a TSA concentration of 0.625 M was 
chosen for the remaining studies to evaluate cells with significantly enhanced insulin 




Figure 3.3: TSA dose response curve with data normalized to GLUTag-INS treated 
with 0 M TSA. TSA concentration effects on viable GLUTag-INS cell number and 
insulin secretion normalized to viable GLUTag-INS cell number were evaluated. All data 
points were statistically different from GLUTag-INS treated with 0 M TSA. 
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Insulin mRNA from high-passaged EINS increased 6.6-fold after a 24h treatment 
with 0.625 M TSA, whereas no difference (p=0.9) in GLUTag-INS mRNA levels was 
detected after treatment (Figure 3.4). If indeed the lentivirus-incorporated insulin transgene 
had been silenced, it is possible that TSA treatment revived its expression in EINS but had 
no effect on the stably transfected insulin transgene in GLUTag-INS. Due to a difference 
in only one amino acid, however, distinguishing between B10 and wild-type human insulin 
is highly complex, making lentivirus-incorporated transgene silencing and reactivation 




Figure 3.4: TSA effects on insulin mRNA levels in GLUTag-INS and EINS, relative 




Similar to EINS insulin mRNA, EINS proinsulin storage was initially 2-fold higher 
than GLUTag-INS and increased 5.5-fold after TSA treatment (Figure 3.5B). Interestingly, 
TSA induced a 2-fold increase in GLUTag-INS proinsulin storage even though mRNA had 
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been unaffected, suggesting a possible effect of TSA on proinsulin independent of 
transcription. Surprisingly, both GLUTag-INS and EINS stored the same amount of insulin 
under either TSA or non-treated conditions (Figure 3.5A), regardless of the fact that 
proinsulin storage was higher in EINS. This was the first discrepancy observed in the EINS 
RSP, in which more stored proinsulin did not result in more stored insulin. Therefore, a 




Figure 3.5: TSA effects on GLUTag-INS and EINS intracellular A) insulin and B) 
proinsulin content normalized to viable cell number. Bars sharing symbols are 
statistically different (*, # p<0.05). 
 
 
While proinsulin storage was higher in EINS versus GLUTag-INS, EINS basal 
proinsulin and insulin secretion were not higher (Figure 3.6). This may suggest that the 
intracellular surplus of proinsulin in EINS was neither converted to insulin for storage nor 
was it secreted. TSA treatment appeared to at least partially alleviate this issue, causing a 
significant increase in EINS proinsulin secretion rates with 50-70% more secreted relative 
to GLUTag-INS. However, the fold-increase in basal proinsulin secretion was higher than 
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the fold-increase in insulin secretion in both cells, implying that conversion in secreting 




Figure 3.6: TSA effects on GLUTag-INS and EINS insulin and proinsulin secretion 
rates normalized to viable cell number. Statistical comparisons are indicated between 
groups under each condition (insulin-basal, insulin-stimulated, proinsulin-basal) and bars 
sharing symbols are statistically different (*, # p<0.05). Statistical comparisons were also 
made between basal and stimulated insulin secretion groups, indicating that stimulated 
secretion was significantly higher than the corresponding basal secretion (p<0.05). 
 
 
In support of storage results, EINS appeared less efficient in converting 
intracellular proinsulin to insulin under either TSA-treated or non-treated conditions (Table 
3.1). Additionally, EINS intracellular processing efficiency declined from 95% to 91% 
after TSA treatment while GLUTag-INS processing efficiency remained the same. Perhaps 
prohormone convertases were able to keep up with the 2-fold increase in GLUTag-INS 
proinsulin, but were unable to remain as efficient after the 5.5-fold increase in EINS 
proinsulin. In support of secretion rate results, secretion processing efficiencies in 
 
59 
GLUTag-INS and EINS were comparable under both conditions, with both declining 
significantly after TSA treatment. This could again suggest that low proinsulin conversion 
in secreting vesicles limited basal insulin secretion. 
 
 
Table 3.1: Mean proinsulin to insulin conversion efficiencies ± standard deviation 
with and without TSA treatment were determined separately for intracellular and 
secreted steps in the RSP of GLUTag-INS and EINS cells. Secreted protein 
measurements were made from samples of basal medium (5 mM glucose) that were taken 
after a two hour incubation period. Percentages were calculated by dividing the insulin 
quantity by the total quantity of insulin and proinsulin. Statistical comparisons were made 
separately for intracellular and secreted processing efficiencies (each column). An asterisk 
identifies efficiencies that are statistically different from non-treated GLUTag-INS and 
efficiencies sharing a # symbol indicates that they are statistically different from one 




Overall, TSA-treated EINS had the highest insulin secretion rates, highest 
proinsulin secretion and intracellular content, and highest insulin mRNA levels (Table 3.2). 
Interestingly, TSA-treated GLUTag-INS were the second highest insulin secretors even 
without insulin mRNA enhancement, suggesting that TSA can also act on mechanisms 
other than insulin transcription to augment secretion. However, since the only difference 
between GLUTag-INS and EINS was the additional lentivirus-incorporated insulin 
transgene in EINS, mRNA enhancement likely played some role in secretion improvement. 
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Table 3.2 displays the intracellular and secreted proinsulin buildup, especially under TSA-
treated conditions. Further studies should be pursued to investigate methods that relieve 
these bottlenecks in the RSP. 
 
 
Table 3.2: Effects of TSA on insulin mRNA levels and various stages of the RSP of 
GLUTag-INS and EINS, represented as a fold-difference from non-treated GLUTag-
INS. Basal secretion results are represented under the proinsulin and insulin secreted 
column. Average non-treated GLUTag-INS values were mRNA-1.0, intracellular 
proinsulin-4.2 fmol/105 cells, intracellular insulin-142 fmol/105 cells, basally secreted 




3.4.3 Long-Term Effects of a 24h TSA Treatment 
EINS were chosen for the long-term TSA study because they were the most 
promising insulin secretors in short-term studies. A 3D environment was chosen because 
it was better at sustaining viable cell numbers over time than the 2D monolayers (data not 
shown) and alginate microcapsules have shown promise as a pancreatic substitute 
configuration in preclinical studies [21]. After a 24h TSA treatment, cells were 
microencapsulated and cultured in vitro for fourteen days. Insulin secretion was 70-80% 
higher after TSA treatment one day post-encapsulation (two days after TSA treatment) and 
was sustained for seven days in culture (Figure 3.7). By day 14, however, secretion was no 
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longer enhanced; insulin mRNA and intracellular insulin had also significantly declined by 
day 14. Even on day 7, a dramatic decline in insulin mRNA was observed, but this appeared 
to have no effect on secretion. It was only until day 14 that intracellular and secreted insulin 
significantly declined to pre-treatment levels. This further strengthens the short-term study 





Figure 3.7: Long-term TSA effects on basal and stimulated ISR normalized to 
alamarBlueTM, intracellular insulin content normalized to alamarBlueTM, and insulin 
mRNA from alginate microencapsulated EINS cells over 14 days. To make TSA fold-
increase comparisons among secreted, intracellular, and mRNA groups, all data were 
normalized to non-treated microencapsulated EINS cells cultured and tested in parallel to 
treated groups. Asterisks indicate a statistical difference from day 1 within each respective 
measurement (*p<0.05). See APPENDIX G for the table of values from non-treated groups 






3.4.4 Effects of HDAC6 Inhibition On Insulin Secretion 
Effects of tubacin on secretion were investigated to determine the role of HDAC6 
in the enhancement observed from TSA treatment (Figure 3.8). Tubacin treatment 
experiments were identical to TSA monolayer treatments, except a final concentration of 
4 M was used instead of 0.625 M. The tubacin concentration was estimated based on 
cytoblot analyses of TSA and tubacin effects on acetylated tubulin levels in A549 cells in 
which a tubacin concentration of roughly 4 M caused a similar increase in acetylated 
tubulin levels as a TSA concentration of approximately 0.625 M [193]. Interestingly, a 
24 hour tubacin treatment had no effect on basal or stimulated secretion from either cell 
line, suggesting that HDAC6 had played no role in secretion enhancement. Tests such as 
this one, with other specific HDACi, may provide more insight into the main mechanisms 








Figure 3.8: Tubacin effects on basal and stimulated insulin secretion from GLUTag-
INS and EINS cells. GLUTag-INS and EINS were treated with tubacin at a final 




Enteroendocrine cells are promising as non- cell sources for diabetes therapy, but 
novel engineering methods need to be developed to generate cells that are capable of 
secreting therapeutic quantities of recombinant insulin. Two enhancement methods, 
lentiviral insulin transgene incorporation and TSA treatment, were applied to GLUTag-
INS cells in this study to generate secretion rates ranging from 655-888 fmol/106 cells-1·h-
1 compared to the range of 384-3930 fmol/106 cells-1·h-1 reported from TC-3 cells [73]. 
These have come the closest to murine  cell line secretion, significantly surpassing 
secretion rates reported from previously engineered enteroendocrine cells that ranged from 
32-204 fmol/106 cells-1·h-1 [16, 18, 125]. In long-term studies, partial secretion 
enhancement effects were sustainable for seven days in alginate microcapsules, suggesting 
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HDAC inhibition as a possible drug therapy for weekly enhancement of transplant 
function. Finally, discrepancies between steps in the RSPs of GLUTag-INS and EINS cells 
have helped to identify proinsulin conversion as a potential target for optimizing insulin 
production. Although insulin mRNA enhancement is probably not essential to insulin 
secretion augmentation, evidence from EINS studies showed that it still contributes to an 
extent. 
Basal secretion rate (75 fmol/106 cells·h), stimulation index (2.4), and proinsulin 
conversion (67%) results from GLUTag-INS cells in this study were similar to those 
reported in initial studies by Bara et al. (86 fmol/106 cells·h; 2.2; 70%). Lentiviral 
transduction of GLUTag-INS cells resulted in a transduction efficiency of 61%, higher than 
in previous studies using plasmid transfection [18] or AAV [125] gene delivery methods.  
It was surprising to find, however, that after FACS, the purified population of EINS 
cells did not exhibit higher secretion rates. Perhaps insulin expression began to decline 
during and after the process of FACS so that the pure EINS population appeared no 
different from eINS. Another possibility is that the fluorescence intensity from some 
transduced eINS cells was lower than the set threshold for FACS and were not accounted 
for during transduction efficiency measurement. The original efficiency, therefore, may 
have been higher than 61% and purifying to 97% had no measurable effect. The difficulty 
in pinpointing the exact cause lies in the separate translation of the insulin and GFP genes, 
enabled by the IRES in the lentiviral vector. For this reason, fluorescence intensity did not 
correlate with insulin expression. 
After lentiviral transduction and minimal passaging, EINS cells were secreting high 
quantities of insulin. Table 3.3 compares the average secretion rate, SI, and proinsulin 
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conversion of TC-3 insulinoma [73] cells, engineered AtT20 [113] cells, engineered NCI-
H716 [125] cells, engineered STC-1 [16] cells, GLUTag-INS [18] cells, and GLUTag-
EINS cells (4-7 passages post-thaw). 
Zhang et al. engineered the mouse STC-1 cells presented in Table 3.3 via stable 
transfection of K cells with the human insulin gene driven by a gastric inhibitor peptide 
(GIP)-specific promoter. Two of 22 isolated clones showed promise: one had decent basal 
insulin secretion (120 fmol/(106 cells·h)) but a low SI (1.4), and the other had a better SI 
(2.2), but basally secreted less insulin (32 fmol/(106 cells·h)). In our study, the ISR from 
EINS cells was 25% higher than the best secreting K cell clone and the SI was comparable 
to the more responsive K cell clone. We were therefore able to engineer one L cell line 
with both a good SI and high secretion capacity. 
Variable, and sometimes conflicting results have been reported among groups using 
the heterogeneous STC-1 cell source to genetically engineer enteroendocrine cells. This is 
likely due to the additional complexity involved in engineering a mixed cell population 
since it requires the use of cell-specific promoters for targeted genetic incorporation. Using 
this approach, some groups have generated satisfactory insulin-secreting [15, 16], glucose-
sensitive K cells [15-17] while others could not engineer glucose-responsiveness [194] or 
gain secretion above 2-11 fmol/(106 cells·h) [100, 195]. In the present study, using the 
homogeneous GLUTag L cell line has eliminated the need for cell-specific promoters, 
thereby simplifying the approach and allowing us to use a strong CMV promoter to drive 




Table 3.3: Comparisons of average basal and stimulated secretion rates, stimulation medium conditions, SI, and proinsulin 
conversion of TC-3 insulinoma [73, 196]* cells, engineered AtT20 [113] cells, engineered NCI-H716 [125] cells, engineered STC-1 






Although transgene incorporation via lentivirus into GLUTag-INS was highly 
efficient, ten times more insulin mRNA in early passages of thawed EINS cells was only 
accompanied by a 1.7 to 2-fold increase in secretion. Transcriptional enhancement was 
therefore beneficial, but not in itself sufficient to significantly boost secretion to therapeutic 
levels. Furthermore, lentiviral-mediated transgene delivery was not a suitable method for 
stable gene expression in GLUTag-INS cells since secretion enhancement was eventually 
lost over passaging. Gene silencing can be an issue when using AAV, retroviruses, and 
lentiviruses for transgene delivery and even the presence of a CMV promoter has been 
associated with gene silencing [89-91]. As in other studies, inhibiting HDACs in 
lentivirally transduced EINS cells with TSA may have reversed gene silencing and 
reactivated transgene expression [92, 93]. 
Although HDACs were originally named for their action on histone proteins, recent 
findings have shown that they also play a role in 875 other classes of proteins [197]. Our 
findings indicated that TSA treatment did not solely affect transgene transcription, but it 
also had effects on downstream steps in the RSP. This was most clearly seen after TSA 
treatment of GLUTag-INS cells when intracellular and secreted proinsulin and insulin 
levels increased even though no difference was observed in insulin mRNA levels. 
Additionally, long-term studies showed that secretion enhancement effects were still 
present even after insulin mRNA declined back to original levels.  
The approximate half-maximal effective concentration range (EC50 = 156-625 nM) 
of TSA on insulin secretion in this study was similar to a study with cytoblot assay images 
indicating an EC50 range (200-1000 nM) of TSA on -tubulin acetylation in the human 
alveolar epithelial A549 cell line [193]. Dompierre et al. reported that TSA increased -
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tubulin acetylation in neuronal cells, leading to an increase in the vesicular transport of 
BDNF, and enhanced BDNF secretion [190]. Treatment with tubacin, a specific HDAC6 
inhibitor, had the same effects as TSA and HDAC6 was identified as a potential target for 
Huntington’s disease. In this work, tubacin treatment of GLUTag-INS and EINS cells had 
no effect on secretion, suggesting that HDAC6 inhibition did not play a role in the secretion 
enhancement observed from TSA treatment. Further studies with specific HDACi may help 
to identify the key mechanisms for secretion augmentation to develop novel, targeted 
treatment options. 
Out of all the non- cell sources that have been investigated, enteroendocrine cells 
appear to be the most promising because their endogenous functions are so similar to 
natural  cells. This study has narrowed down promising research avenues for developing 
a successful enteroendocrine cell-based diabetes therapy. Cellular engineering studies can 
focus on relieving bottlenecks in the RSP such as those identified in this work. HDACi can 
be investigated as a novel drug therapy for enhanced transplant function since long-lasting 
effects of HDAC inhibition by TSA were observed for seven days in culture. Future work 
should include long-term in vitro and in vivo studies to optimize the HDACi treatment 
protocol. Perhaps periodic treatment in small doses will better augment secretion in a 
sustained manner. As TSA acts on ten different HDACs, an in-depth mechanistic study 
should be pursued to identify specific HDACi that augment L cell secretion to develop 




CHAPTER 4: DEVELOPMENT AND IN VITRO 
CHARACTERIZATION OF A BIOLUMINESCENT PANCREATIC 




Cell-based insulin therapies can potentially improve glycemic regulation in insulin 
dependent diabetes patients. Enteroendocrine cells engineered to secrete recombinant 
insulin have exhibited glycemic efficacy, but are primarily studied as uncontrollable 
growth systems that lead to tumor formation. Encapsulation is a strategy for controlling 
cell growth, but has precluded therapeutic efficacy, possibly due to suboptimal construct 
designs. In addition, critical factors that influence graft outcome in vivo are difficult to 
delineate. In this study, tissue engineering strategies were applied to design an optimized 
encapsulation configuration for enhanced recombinant insulin secretion on a per-graft 
basis. To provide a growth-controlled and immune protective environment without 
affecting secretion, cells were microencapsulated in barium alginate. We were able to 
observe an approximate 100-fold increase in secretion relative to a macrocapsule construct 
previously fabricated in our lab. In addition, with the goal of enhancing graft fate 
understanding, stable bioluminescence was incorporated via luciferase lentivirus 
transduction and microencapsulation effects on signal and tracking capabilities were 
studied. Although it has been popular in tracking survival of free cells, little is known of 
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the ability for bioluminescence to track encapsulated cells. Data showed that 
microencapsulation had no effect on bioluminescence signal and allowed for real-time cell 
tracking under conditions of normoxic growth and anoxia-induced death. In this work, we 
have developed a bioluminescent, controlled-growth non- cell pancreatic substitute that, 
at a 3 mL graft volume, comes the closest to therapeutic insulin output compared to 
previous enteroendocrine constructs. The next step is to test whether a secretion of 16-24 
mU of human insulin/day is therapeutically meaningful in a preclinical diabetes model. 
 
 Introduction 
Cell-based therapies are under development to replace current treatment options for 
diabetes, as they offer significant promise in providing improved regulation of daily blood 
glucose levels by continuously, rather than discretely, restoring homeostasis. In particular, 
engineering and transplanting autologous non- cell sources could address donor cell 
scarcity and avoid autoimmune destruction [184]. Although non- cell candidates like 
engineered intestinal endocrine cell lines have restored normoglycemia in preclinical 
diabetes models, tumor formation has prevented its clinical applicability [15, 16]. 
Encapsulated configurations can control cell growth, but have stymied therapeutic efficacy 
[17, 20]. A probable hindrance to success is suboptimal construct design, but the critical 
factors that influence graft outcome in vivo are difficult to delineate. There is a need to 
improve controlled-growth non- cell systems and expand in vivo graft fate understanding. 
This need may be partially addressed by altering the encapsulation configuration. 
In fabricating an encapsulation device, the choice of biomaterial, cell loading capacity, and 
preservation of cell function are critical factors [198]. Bara et al. seeded human insulin-
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secreting L cells in a macrocapsule device for transplantation [18-20], but blood glucose 
levels were unaffected; detecting human insulin in the blood was, however, promising. 
Unniappan et al. found that alginate microencapsulated insulin-producing intestinal K cells 
were also unable to control blood sugars until a drug-inducible element was incorporated 
into the insulin transgene [17]. Limitations imposed by the choice of encapsulation 
configuration may have been partially responsible for their failure as standalone diabetes 
treatments. 
Limitations to the macrocapsule device fabricated by Bara et al. were its inability 
to load high cell densities and its significant detriment to apparent insulin secretion rates 
per cell relative to secretion from unencapsulated cells grown on tissue culture plastic, 
perhaps due to delayed diffusion via mm length scales between cells and the in vivo 
environment [21]. One of the major disadvantages in vivo was construct weakness and 
breakage observed from explanted constructs, which was the likely cause for immune 
attack [41]. 
Instead of using a macrodevice, Unniappan et al. developed engineered K cell grafts 
by applying a microcapsule configuration [17]. Such a configuration should better prevent 
capsule breakage, permit nutrient diffusion over micron length scales, and allow for high 
cell density loading. However, Unniappan et al. were still unable to achieve therapeutic 
efficacy in diabetic mice in the absence of a drug-inducible element and periodic drug 
administration. A potential limitation to the study may have been the choice of 1.5% 
sodium alginate and a calcium chloride cross-linking solution which was found by 
Duvivier-Kali et al. to result in significantly more capsule overgrowth and breakage in vivo 
compared to 3.3% (wt/vol) alginate microcapsules cross-linked in barium chloride solution 
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[149]. Although the major reason for therapeutic failure was likely insufficient insulin 
secretion per engineered K cell, neither fibrosis nor microcapsule breakage were reported, 
which may have at least partially contributed to in vivo graft failure. 
Previous configurations that have been applied to insulin-secreting enteroendocrine 
cells should be improved by optimizing diffusion, cell loading density for sufficient insulin 
output, and biomaterial composition for reduced breakage and host response. Although 
optimizing these factors are believed to be important, the data do not exist from previous 
studies which ascertain the precise causes for engineered enteroendocrine graft failure in 
vivo. For this reason, the development process is slower than it should be and methods must 
be developed which allow researchers to isolate the key factors that contribute to graft 
failure. 
In most cases, graft efficacy is assessed by endpoint measurements from the animal 
model, which offers limited information into what is happening to the graft itself. The 
efficacy of insulin-secreting cell grafts is typically evaluated by measuring blood glucose, 
plasma C-peptide, and glycosylated hemoglobin levels [165]. However, these 
measurements do not allow for direct monitoring of the graft or the identification of 
probable causes of failure. 
Magnetic resonance imaging (MRI) has been identified as a suitable tracking 
method for in vivo graft monitoring [176, 177], with its own advantages and limitations 
[178]. Some studies have investigated the application of 19F nuclear magnetic resonance 
(NMR) spectroscopy to measure the oxygen concentration at the graft site in mice post-
transplantation of microencapsulated  cells [179, 180]. This method, however, only 
allowed for indirect graft monitoring. Alternatively, 1H NMR has been applied for direct 
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monitoring of encapsulated  cells, but the macrocapsule construct design that allowed for 
such monitoring was not optimal for cell function [181]. The ideal monitoring method 
should allow for minimally-invasive in vivo real-time tracking of the transplant while 
preserving construct design for optimal graft function. 
Bioluminescence imaging (BLI) is a powerful tool to directly monitor cell fate in 
animals due to its low cost, high sensitivity, ease of operation, near background-free 
imaging conditions, and reduction of inter-animal variability [165, 166]. The first proof-
of-concept BLI study with free islets offered encouraging results, as it demonstrated that 
islets transduced in vitro with a luciferase lentivirus could be quantitatively monitored 
long-term after transplantation in the kidney capsule of diabetic mice [167]. Subsequent 
studies investigated the use of BLI in early detection of islet graft rejection [168], islet 
survival immediately post-transplantation [169], and guided timing for corrective 
interventions [170].  
As the field progressed into using tissue engineered microencapsulation strategies, 
BLI incorporation did not follow. Some studies have applied BLI to macrocapsule or fixed 
systems that retained the cells at a particular anatomic locale [171-174], but these strategies 
lack certain advantages of freely floating microcapsules [184] and may not be optimal for 
cell function. Quantitative effects of microencapsulation on BLI signal and real-time cell 
survival tracking capabilities remain unknown. 
In this work, we altered previous encapsulation configurations and applied a BLI 
method to develop an optimized, controlled-growth non-cell pancreatic substitute with 
real-time monitoring capabilities. In addition, we used the early passage GLUTag-EINS 
cells previously engineered in our lab, based on the GLUTag-INS cell line [18], with 
 
74 
significantly enhanced recombinant insulin secretion. We demonstrated that our 
microcapsule configuration permitted insulin secretion and BLI signal detection, and that 
in vitro quantitative BLI could be used for real-time survival tracking of encapsulated cells 
under conditions of growth and anoxia-induced death. The implications of developing such 
a pancreatic substitute for preclinical efficacy will be discussed. 
 
 Materials and Methods 
4.3.1 Luciferase Reporter Gene Incorporation 
GLUTag-EINS (EINS) cells were seeded at a density of 1x105 cells/cm2 in a 24-
well plate. Cells were transduced with firefly luciferase lentivirus (F-Luc Lentivirus; 
Capital Biosciences, Rockville, MD) at a Multiplicity of Infection (MOI) of 30 following 
the company’s protocol, expanded, passaged, and conventionally frozen as a new cell line: 
GLUTag-EINS-Fluc (Fluc). The lentiviral vector contained the luciferase reporter gene 
driven by the constitutive cytomegalovirus (CMV) promoter. 
 
4.3.2 Cell Microencapsulation and Culture 
EINS and Fluc cells were microencapsulated in LVM alginate (LVM; Novamatrix, 
Drammen, Norway) cross-linked in 30 mM BaCl2 solution using an electrostatic droplet 
generator (Nisco Engineering, Zurich, Switzerland), as previously described [180]. The 
diameter of the resulting microcapsules was 730 ± 94 m (average ± standard deviation). 
Microencapsulated EINS and Fluc cells were cultured in non-treated T-75 flasks in 
Dulbecco’s modified Eagle’s medium (DMEM) with 25 mM glucose, without L-glutamine 
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(Corning cellgro, Manassas, VA), and supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Cultures were kept on a rocker plate in a humidified incubator at 
37oC/5% CO2. 
 
4.3.3 In Vitro BLI Characterization 
4.3.3.1 BLI and Metabolic Activity Correlations 
To determine the effect of microencapsulation on BLI and metabolic activity 
correlations, cultures of Fluc monolayers and microcapsules were initiated at varying cell 
numbers ranging from 0.3-2x106 cells; bioluminescence and metabolic activity were 
measured one day later. In all studies, metabolic activity was measured using alamarBlueTM 
(Life Technologies, Grand Island, NY) as previously described [192] with an incubation 
period of one hour. Two independent experiments were performed at four different cell 
numbers each, resulting in eight data points for each correlation. 
 
4.3.3.2 Growth and Death Characterization 
To characterize BLI tracking of cell growth in microcapsules, microencapsulated 
Fluc cells were cultured for a period of 17 days. Metabolic activity, total DNA, light 
microscopy images, and BLI were obtained on days 1, 3, 7, 11, 14, and 17. Data were 
compared to day 1 for statistical analysis. 
To evaluate real-time BLI response to microencapsulated cell death, a fraction of the 
microcapsule population (corresponding to approximately 6 x 106 cells) was transferred on 
day 14 to tubes containing 2 mL unsupplemented DMEM (Sigma, St. Louis, MO) with 5 
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mM glucose; tubes were hermetically sealed with no gas headspace. Anoxic conditions 
arose due to oxygen consumption by cells. Prior to measurement, microcapsules from tubes 
were cultured under normoxic conditions for one hour to allow recovery of any living cells. 
Metabolic activity and bioluminescence were measured every 12 hours in the first 36 hours 
post-sealing to capture the initial dynamic phase of cell death and an additional sample was 
taken at 84 hours to ascertain any additional cell death at later time points.  
For DNA measurements, 0.1 mL capsules were solubilized in 
ethylenediaminetetraacetic acid disodium salt dihydrate solution (ED2SS; 0.2 M; pH 9) for 
three minutes, then DNA purification (Mammalian cell lysis kit; Life Technologies) and 
Quant-iT PicoGreen dsDNA assay (Life Technologies) were performed according to the 
manufacturer’s protocols.  
 
4.3.4 Pancreatic Substitute Fabrication 
Insulin secretion rate (ISR) tests were performed on EINS and Fluc cells passaged 
3-7 times post-lentiviral transduction. Monolayers were seeded in 12-well plates and 
subjected to basal conditions (DMEM with 5mM glucose) for two hours followed by a two 
hour step-up period under stimulating conditions (basal medium with 2% meat hydrolysate 
(MH); Sigma). Insulin measurements were made using an insulin radioimmunoassay (RIA; 
Millipore, Billerica, MA). 
 One and fourteen days post-encapsulation, ISR tests were performed on 0.1 mL 
volumes of microcapsules in 100 m strainers placed in 12-well plates. Viable cell counts 
were only possible one day post-encapsulation, before cell aggregation within 
microcapsules prevented reliable hemacytometer cell counting. For this reason, metabolic 
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activity measurement via alamarBlueTM was used to track viable microencapsulated cells 
over time. After an ISR test, microcapsules were either solubilized for trypan blue (Sigma) 
viable cell counting or incubated in alamarBlueTM for one hour. 
 
4.3.5 Bioluminescence Imaging 
Bioluminescence imaging was performed using the IVIS Lumina (Perkin Elmer, 
Grayson, GA). Once the sequence was acquired, photon emission was quantified from a 
selected region of interest (ROI). In vitro monolayers and microencapsulated cells were 
imaged in 12-well plates by adding D-luciferin (RPI Corp, Mount Prospect, IL) at a final 
concentration of 180 mg/mL immediately before imaging. The ROI and settings were kept 
constant for all experiments. 
 
4.3.6 Statistical Analysis 
All data were analyzed using Minitab software (Minitab, Inc., State College, PA) and 
reported as mean ± standard error; each mean was the average of data from three or more 
independent experiments. Significance was determined using a one-way analysis of 
variance (ANOVA) with the general linear model, with significance defined as p≤0.05. 
 
 Results and Discussion 
4.4.1 Bioluminescence Incorporation 
Fluc monolayers expressed a stable bioluminescence signal of 80 photons cell-1 s-1 
(Figure 4.1A). Basal and stimulated ISR from Fluc cells were comparable to EINS cells, 
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and remained significantly higher than the non-transduced GLUTag-INS cells (Figure 
4.1B). Insulin secretory function was, therefore, preserved after luciferase lentivirus 
transduction. 
 
4.4.2 BLI Characterization 
4.4.2.1 BLI and Metabolic Activity Correlations 
Microencapsulation of Fluc cells within Ba2+ cross-linked alginate resulted in no 
attenuation of bioluminescence signal. Additionally, microencapsulation did not change 
the close correlation between metabolic activity and bioluminescence over varying cell-
seeding densities (Figure 4.2A). A similar positive correlation was also observed in 
temporal studies where cells proliferated within microcapsules for 14 days (Figure 4.2B); 
the higher variability of the data noted in this case was likely due to differences in cell 
aggregation and remodeling within microcapsules over time. Figure 4.3 is a pictorial 
representation of the positive correlation between cell proliferation and bioluminescence 


















Figure 4.1: Bioluminescence incorporation into EINS cells via luciferase lentivirus 
transduction. A) Stable bioluminescence signal from Fluc monolayers over several 
passages post-transduction. B) Bioluminescence incorporation had no apparent effect on 
















Figure 4.2: The strong positive correlation between bioluminescence and metabolic 
activity of Fluc cells remained the same after microencapsulation and during 
proliferation in culture. A) Cell monolayer and microencapsulated cell correlations one 
day after seeding at varying cell densities. B) Microencapsulated cell correlation with cells 
allowed to proliferate over 14 days in vitro. The number of days after encapsulation are 





Figure 4.3: Representative bright field microscopy images of a single microcapsule 
over 17 days in culture (top row) and BLI images of a 0.1 mL microcapsule volume 
in a single well of a 12-well plate over 17 days (bottom row). Days post-encapsulation 
are indicated by d1, d3, d11, d14, and d17. 
 
 
4.4.2.2 Growth and Death Characterization 
To fully characterize the monitoring capabilities of bioluminescence from cells 
growing within microcapsules, Fluc cells were encapsulated and tracked for 17 days in 
vitro. Bioluminescence signals exhibited similar levels of increase to metabolic activity 
and total DNA until day 7 to 12 post-encapsulation; this increase was followed by a plateau 
for the remainder of the study (Figure 4.4). This plateau was likely due to an eventual 
equilibrium between cell growth and death, which is reached at a viable cell density that 
depends on the capsule characteristics and surrounding oxygen concentration [199, 200]. 
Total DNA appeared to take longer to plateau relative to bioluminescence and metabolic 
activity (Figure 4.4B), likely resultant from accumulation of both viable and non-viable 
cellular DNA within the microcapsules over time. On the other hand, BLI captured growth 




Figure 4.4: Bioluminescence tracked metabolic activity trends of microencapsulated 
Fluc during cell growth in culture. A) Metabolic activity measured by alamarBlueTM, B) 
total DNA, and C) bioluminescence signal were followed over time in culture for 17 days. 
For each time point and measurement, a 0.1 mL volume of microcapsules was sampled 
from each culture. *p<0.05: Statistically higher than day 1. 
 
 
To determine the response time of bioluminescence signal to cell viability loss, 
death of microencapsulated cells was prompted by anoxia. Cell death due to reduced 
dissolved oxygen is physiologically relevant, as severe hypoxia occurs in the peritoneal 
cavity especially after transplantation of encapsulated cells [179, 180]. After stopping 
culture oxygenation, a significant decline in bioluminescence signal occurred over twelve 
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hours followed by a more gradual decrease until the end of the experiment at 84 hours. 
Again, bioluminescence signal closely tracked the metabolic activity with no apparent time 




Figure 4.5: Bioluminescence tracked the decline in metabolic activity of 
microencapsulated Fluc in real-time over 84 hours during cell death induced by 
anoxia.  *p<0.05: Statistically lower than at 0 h. 
 
 
4.4.3 Pancreatic Substitute Fabrication 
Microencapsulation had no apparent effect on insulin secretion per cell and no 
statistical difference existed between EINS and Fluc secretion one day post-encapsulation 
(Figure 4.6B). However, 14 days post-encapsulation, less secretion per Fluc microcapsule 
volume was observed (Figure 4.6C) while the stimulation index remained the same (Figure 
4.6D). Interestingly, Fluc exhibited 52% less metabolic activity, as assessed by 
alamarBlueTM, than EINS on day 14 possibly due to slower Fluc cell growth within 
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microcapsules leading to lower insulin output per microcapsule. These data instigated the 
fabrication of a mixed microcapsule system consisting of mostly EINS to maximize insulin 




Figure 4.6: In vitro pancreatic substitute fabrication and characterization. A) Basal 
and stimulated ISR from GLUTag-INS, GLUTag-EINS, and GLUTag-EINS-Fluc cell 
monolayers. B) ISR normalized to viable cell number from microencapsulated EINS and 
Fluc cells one day post-encapsulation. C) ISR per mL volume of microencapsulated EINS 
and Fluc cells 1 and 14 days post-encapsulation (d1 & d14). D) Stimulation indices 
(stimulated/basal ISR) of microencapsulated EINS and Fluc cells 1 and 14 days post-
encapsulation. Shared symbols above bars indicate significant differences (*, #, ^ p<0.05). 
In Figure A, statistical comparisons were made between basal and stimulated data for each 
group and between groups for each condition. In Figures B-C, statistical comparisons were 





Estimates of transplant volumes that would be required to normalize glycemia were 
based on reported insulin secretion from microencapsulated TC-tet cells that restored 
normoglycemia in STZ-induced diabetic mice upon i.p. injection [180]. EINS data from 
Figure 4.6 indicated that 7.5 mL microcapsules would need to be transplanted to match 
TC-tet graft secretion. Due to mouse model space restrictions however, 3 mL 
(corresponding to 9x107 EINS cells or 42% of TC-tet graft secretion) will be the 
maximum volume attempted for transplant (Table 4.1). Based on these approximations, 




Table 4.1: Estimated therapeutic potential of GLUTag-EINS grafts based on 




Altering the previous macrocapsule configuration (agarose disc construct 
containing GLUTag-INS cells) to 3.3% high mannuronic acid alginate microcapsules 
cross-linked in barium chloride solution containing the enhanced GLUTag-EINS cells 
resulted in a superior controlled-growth graft that secreted roughly 100-fold more insulin 
per day than the macrocapsule graft formerly developed [19]. The microcapsule 
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configuration allowed for 3.5-fold higher cell loading densities (3.0x107 cells/mL alginate 
versus 8.6x106 cells/mL agarose) and 30-fold more total cell numbers in one, 3 mL graft 
volume (9.0x107 cells) compared to the 350 L macrocapsule construct that supported only 
3.0x106 viable cells. 
Contrary to the macrocapsule device which significantly hindered the apparent 
insulin secretion rate per cell, alginate microencapsulation had no such effect. The 3.3% 
barium alginate microcapsule configuration was also applied to prevent host cell 
overgrowth and capsule breakage which have been observed in previous studies of calcium 
alginate microcapsules [149]. The goal is to minimize host cell adhesion to the semi-
permeable alginate membrane and therefore minimize the blockage of nutrient and insulin 
diffusion to and from the transplanted cells. Additionally, minimizing capsule breakage 
will in effect minimize the host response. In order to determine whether the configuration 
is advantageous in this way, it will be evaluated in therapeutic efficacy studies. 
A BLI system was established in the same pancreatic substitute for temporal 
monitoring of microencapsulated cells. Although these microencapsulated cell transplants 
are a common configuration, BLI has not previously been applied to such a system. In vitro 
studies elucidated that luciferase lentivirus transduction resulted in stable bioluminescence 
signal without seriously compromising insulin secretion. In addition, microencapsulation 
had no effect on BLI signal and bioluminescence closely tracked temporal changes due to 
cell growth and anoxia-induced death within microcapsules. With real-time monitoring 
BLI capability such as this in vitro, it can be reasonably expected that the graft will show 
similar capabilities in vivo and help to identify key factors that contribute to graft failure. 
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In this work, we have developed a bioluminescent, controlled-growth non-cell 
pancreatic substitute that comes the closest to therapeutic insulin secretion output when 
compared to successful  cell diabetes therapies and is the first with real-time monitoring 
capabilities. The next step is to test the therapeutic efficacy of transplanting this developed 
construct, based on engineered L cells, in a preclinical diabetes mouse model. 
 
*Modification of a paper published in Transplantation (in press) 
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CHAPTER 5: IN VIVO THERAPEUTIC EFFICACY AND 
SURVIVAL EVALUATION OF AN ENHANCED, 
BIOLUMINESCENT PANCREATIC SUBSTITUTE* 
 
 Abstract 
Cell-based insulin therapies can potentially improve glycemic regulation in insulin 
dependent diabetes patients. Enteroendocrine cells engineered to secrete recombinant 
insulin have exhibited glycemic efficacy, but are primarily studied as uncontrollable 
growth systems in immune incompetent mice. In addition, reports suggest that suboptimal 
insulin secretion and the absence of real-time tracking methodologies remain barriers to 
expanded application. Genetic and tissue engineering strategies were previously applied to 
optimize recombinant insulin secretion from intestinal L cells on both a per-cell and per-
graft basis; the luciferase reporter gene was also incorporated for bioluminescence (BLI) 
monitoring. To provide a growth-controlled and immune protective environment without 
affecting secretory capacity or BLI signal, cells were microencapsulated in barium alginate. 
In vivo BLI was characterized in normal mice at subtherapeutic cell numbers and 
approximately 9 x 107 microencapsulated cells were injected intraperitoneally in immune-
competent streptozotocin-induced diabetic mice for therapeutic efficacy evaluation. 
Transient normoglycemia was achieved in treated mice two days after transplantation, and 
endogenous insulin was sufficient to sustain body weights of treated mice receiving 
minimal supplementation. Glycemic efficacy of a bioartificial pancreas based on insulin 
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secreting enteroendocrine cells is insufficient as a standalone therapy, despite enhancement 
of graft insulin secretion capacity. Supplemental strategies to alleviate secretion limitations 
should be pursued. 
 
 Introduction 
In 2011, the CDC reported that 25.8 million people in the United States alone are 
affected with Diabetes, and 6.7 million of them are dependent on insulin [1]. To prevent 
long-term complications in patients with insulin dependent diabetes (IDD), blood glucose 
levels must be tightly regulated with multiple daily insulin injections or continuous 
subcutaneous insulin infusion (CSII) by pump [2]. Even with diligent monitoring and 
insulin administration, many patients fail to achieve recommended control of their blood 
sugars. There is a clear need for a diabetes treatment that improves glycemic regulation 
without further burdening patients, to reduce morbidity and improve quality of life. 
 A cell-based approach, islet transplantation, has had some clinical success in 
addressing this need. However, widespread use is still hindered by islet scarcity and 
immune rejection producing limited durability [3]. These hurdles have motivated 
researchers to explore the possibility of using autologous non- cells as a replacement 
therapy, by engineering the diabetic patient’s own healthy non- cells to become meal or 
glucose-responsive insulin secretors. Three enteroendocrine cell types, gastric G cells [12], 
intestinal L cells, and intestinal K cells [13], inherently possess a secretory mechanism like 
 cells. These cells also express the necessary prohormone convertases for proinsulin to 
insulin processing, making them promising  cell surrogate candidates.  
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Initial proof-of-concept studies showed that mice transgenic for human insulin-
secreting K cells were resistant to streptozotocin (STZ)-induced diabetes [12]. Similarly, 
insulin-secreting G cells significantly reduced mouse blood glucose levels [14]. The 
engineering of enteroendocrine cells, such as K cells isolated from the heterogeneous 
immortalized STC-1 cell line [15, 16] and stably transfected with an insulin transgene, have 
permitted preclinical evaluation without resorting to transgenics. Insulin-secreting K cell 
clones were selected and tested for efficacy after cell transplantation into diabetic mice. 
Both studies reported restoration of normoglycemia, but mice became hypoglycemic as 
unrestricted cell proliferation increased insulin production beyond therapeutic levels. 
Additionally, immune-incompetent mice were used as the preclinical model to avoid 
transplant rejection.  
Encapsulating cells to control cell growth and provide immune protection, and 
transplanting in immune-competent diabetic mice addressed both issues. Unniappan et al. 
found that microencapsulated insulin-producing K cells were unable to control blood 
sugars until a drug-inducible element was incorporated into the insulin transgene [17]. 
Alternatively, Bara et al. seeded human insulin-secreting L cells in a macrocapsule device 
for transplantation [18-20]. Human insulin was detected in mouse plasma, but blood 
glucose levels were unaffected. Insufficient insulin secretion and limitations imposed by 
macrocapsules were two likely barriers that prevented these controlled-growth 
enteroendocrine cell systems from serving as standalone diabetes treatments. In addition, 
the inability to delineate the critical factors that influenced graft survival and function over 
clinically relevant time scales should be addressed to accelerate therapy development. 
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Bioluminescence imaging (BLI) is a powerful tool to directly monitor cell fate in 
animals, but it remains unknown whether free microcapsules, a routine transplant 
configuration for insulin therapy [152, 179, 201-205], can indeed be successfully 
monitored in vivo using BLI. A potential barrier to achieving real-time BLI indications of 
graft survival using this configuration is increased imaging distances that could result from 
dynamic in vivo microcapsule dispersion. It is therefore important to determine whether 
such an approach is worth pursuing. 
In the first part of this study, we evaluated the extent to which free injectable 
alginate microcapsules containing insulin-secreting, bioluminescent intestinal L cells could 
be monitored in vivo for survival via BLI. We have demonstrated that in vivo graft survival 
can be identified by BLI measurements consistently above background in mice following 
transplantation by intraperitoneal (i.p.) injection. In the second part of this study, we report 
the therapeutic effects of enhanced insulin-secreting and bioluminescent L cells, based on 
recombinant GLUTag cells [18], that were microencapsulated in barium alginate and 
transplanted i.p. in STZ-diabetic mice. We discuss the implications of this study in the 
context of a standalone enteroendocrine cell therapy and the potential benefit of a dual cell 
therapy for complete normoglycemic restoration. 
 
 Materials and Methods 
5.3.1 Cell Lines and Culture Conditions 
GLUTag-INS [18], GLUTag-EINS (EINS), and GLUTag-EINS-Fluc (Fluc) cells 
were cultured as in [191] using Dulbecco’s modified Eagle’s medium (DMEM) with 25 
mM glucose, without L-glutamine (Corning cellgro, Manassas, VA), and supplemented 
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with 10% fetal bovine serum and 1% penicillin/streptomycin. Cultures were propagated in 
a humidified incubator at 37oC/5% CO2. The EINS cell line had been generated by 
transduction of GLUTag-INS with the wild-type human insulin lentivirus (WT-INS; 
Emory University; Dr. John Shires) and the Fluc cell line had been generated by 
transduction of EINS with the firefly luciferase lentivirus (Capital Biosciences, Rockville, 
MD). 
 
5.3.2 In Vivo BLI Characterization 
All procedures were approved by the Georgia Institute of Technology’s Animal 
Care and Use Committee. Seven week old male BALB/c mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). On day 0, Fluc cells were encapsulated at 3x107 
cells/mL alginate, and a 1 mL capsule volume was transplanted i.p. through an 18 gauge 
needle in each of six mice under isoflurane anesthesia, while an approximate 1 mL volume 
was cultured in parallel in vitro for direct comparison. Cell-free microcapsules were 
transplanted in one mouse as a negative control. To monitor possible hypoglycemia, 
glucose concentrations were measured in blood samples collected from the tip of the tail 
using a TRUEtrack glucose monitor (Nipro Diagnostics, Fort Lauderdale, FL). 
Bioluminescence images were acquired from in vivo and in vitro groups on days 3, 7, 11, 
14, and 17 post-transplantation.  
Three mice were euthanized on each of days 11 and 17. These two days were 
carefully chosen in order to gain mid- and end-point in vivo graft insight without 
unnecessarily sacrificing mice for every imaging day. Incisions were made through the 
skin and muscle of the abdomen and capsules were retrieved with a pipette following 
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peritoneal washes. Explanted capsules were cultured under normoxic conditions for two 
hours, then metabolic activity and bioluminescence signal were measured. Other explant 
assessments included light microscopy imaging, live/dead analysis, histology, and insulin 
secretion. Live/dead analysis was performed as in [180] and by following the 
manufacturer’s protocol (LIVE/DEAD® Viability/Cytotoxicity Kit; Life Technologies). 
Hematoxylin/eosin (H&E) histology images of microcapsules were obtained as previously 
described [179] with resin embedding.  
 
5.3.2.1 Statistical Analysis 
All data were analyzed using Minitab software (Minitab, Inc., State College, PA) 
and reported as mean ± standard deviation; each mean was the average of three or more 
independent experiments. Significance was determined using a one-way analysis of 
variance (ANOVA) with the general linear model, with significance defined as p≤0.05. 
 
5.3.3 Therapeutic Efficacy Evaluation 
All procedures were approved by the Georgia Institute of Technology’s Animal 
Care and Use Committee. Six week old male BALB/c mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). Six days before transplantation, diabetes was 
induced by i.p. injection of 180 mg/kg streptozotocin (STZ; Sigma) solubilized in sodium 
citrate solution (22.5 g/L; pH 4.5). Lantus® insulin was injected subcutaneously based on 
a predetermined criteria.  
All microcapsules were fabricated one day before transplantation. On day 0, 
aliquots of microencapsulated EINS (2 mL) and Fluc (1 mL) cells were mixed in five 
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centrifuge tubes (3 mL each). Four tubes were prepared with 3 mL acellular microcapsules 
in each. Microcapsules were then washed eight times in 50 mL unsupplemented high 
glucose DMEM and loaded into 3 mL syringes. Five diabetic mice received the EINS/Fluc 
microcapsules (experimental group; n=5) and four received the acellular microcapsules 
(control group; n=4). Microcapsules were injected i.p. through an 18 gauge needle in mice 
under isoflurane anesthesia. Approximately 1 mL of the EINS/Fluc microcapsule mixture 
was cultured in vitro as a control, run parallel to in vivo groups. 
Random, daily glucose concentrations were measured in blood samples collected 
from the tip of the mouse tail using a TRUEtrack glucose monitor (Nipro Diagnostics, Fort 
Lauderdale, FL); body weight was also measured daily. Mice were fed ad libitum until day 
16 when mice were fasted overnight (16-18 hours) to examine effects of eating. See 
Schematic 5.1 for a visual representation of the efficacy evaluation study. 
 
5.3.3.1 Exogenous Insulin Administration Criteria 
Exogenous insulin (1-2 U Lantus® insulin every two days as long as mice were 
diabetic (higher than 350 mg/dl)) was administered to maintain body weight and avoid 
extreme hyperglycemia (higher than 450 mg/dl). To avoid hypoglycemia (lower than 50 
mg/dl) and adjust for insulin produced by the grafts, transplanted animals only received 1 
U Lantus® for persistently extreme hyperglycemia. 
 
5.3.3.2 Explant Analyses 
Mice were euthanized on day 17 and serum was collected by cardiac puncture, 
incubated in CAPIJECT® blood collection tubes with no additives at room temperature for 
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20 minutes, and centrifuged for 10 minutes at 4o C and 1,600 xg for supernatant collection 
and insulin measurement. Grafts were retrieved by making incisions through the skin and 
muscle of the abdomen and collecting microcapsules with a pipette following peritoneal 
washes. Explant assessments included ISR and intracellular insulin measurement, BLI, 
metabolic activity measurement, live/dead analysis, light microscopy imaging, and 
hematoxylin/eosin (H&E) histological analysis. Live/dead analysis was performed by 
following the manufacturer’s protocol (LIVE/DEAD® Viability/Cytotoxicity Kit; Life 















5.3.3.3 Statistical Analysis 
All data were analyzed using Minitab software (Minitab, Inc., State College, PA) 
and reported as mean ± standard error; each mean was the average of data from three or 
more independent experiments or mice. Significance was determined using a one-way 
analysis of variance (ANOVA) with the general linear model, with significance defined as 
p≤0.05. 
 
5.3.4 Bioluminescence Imaging 
Bioluminescence imaging was performed using the IVIS Lumina (Perkin Elmer, 
Grayson, GA). Once the sequence was acquired, photon emission was quantified from a 
selected region of interest (ROI). Microencapsulated cells (0.1 mL capsule volume) were 
imaged in 12-well plates by adding D-luciferin (RPI Corp, Mount Prospect, IL) at a final 
concentration of 180 mg/mL immediately before imaging. The ROI and settings were kept 
constant for all experiments. For in vivo imaging, mice were placed under isoflurane 
anesthesia (1.2%) and injected i.p. with D-luciferin at 200 mg/kg five minutes before an 
image acquisition of less than 20 seconds. The ROI was auto-adjusted to include the entire 
signal and thus account for microcapsule dispersion that could temporally change the ROI 






5.3.5 Insulin Secretion Rate Test 
ISR tests were performed on 0.1 mL volumes of microcapsules in 100 m strainers 
placed in 12-well plates. Microencapsulated cells were subjected to basal conditions 
(DMEM with 5mM glucose) for two hours followed by a two hour step-up period under 
stimulating conditions (basal medium with 2% meat hydrolysate (MH); Sigma). Media 
samples were taken at 0 and 2 hours (t0, t2-) after adding basal medium and 0 and 2 hours 
(t2+, t4) after changing to stimulation medium. Secretion data from microcapsules were 
normalized to metabolic activity measured by alamarBlueTM (Life Technologies, Grand 
Island, NY) as in [192] using a one hour incubation period. 
 
 Results 
5.4.1 In Vivo BLI Characterization 
In vivo BLI characterization studies were conducted at sub-therapeutic levels in 
normal mice to establish the applicability of BLI to monitoring encapsulated cells in a 
generalizable, simplified animal model without confounding factors related to a diabetic 
state. Sub-therapeutic cell numbers were estimated based on insulin secreted from capsules, 
which was 10-15% of the amount of insulin needed to affect BALB/c glucose homeostasis 
[180]. 
Representative bioluminescence images from two of the six mice injected i.p. with 
a 1 mL volume of microencapsulated Fluc cells over the 17 day experiment are shown in 
Figure 5.1. Image acquisition began three days post-transplantation; high signal intensities 
(on the order of 109 photons/s) were obtained for the entire study duration. A representative 
image of one negative control mouse transplanted with cell-free microcapsules is included 
 
99 
in Figure 5.1 to illustrate the negligible BLI background levels (on the order of 105 
photons/s). A distinct, sustained difference of four orders of magnitude between 
experimental and control groups gave clear indication of graft survival. BLI also allowed 





Figure 5.1: BLI allowed for survival and spatial monitoring of microencapsulated 
Fluc cells for 17 days after i.p. injection in six BALB/c mice. Representative in vivo 
IVIS images are shown from two of the six mice receiving a 1 mL volume of 
bioluminescent microencapsulated cells (different mice are separated by rows). The 
number of days after microencapsulation/transplantation are indicated by columns and 
labeled as d3, d7, d11, d14, and d17. One representative image of the negative control is 




Alongside in vivo studies, microencapsulated Fluc cells were cultured and 
characterized in vitro. Bioluminescence data were compared between the following 
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microcapsule groups: in vitro, in vivo, and microcapsules explanted on days 11 and 17 
(Figure 5.2A). Comparable trends were observed between the in vitro and in vivo groups 
except on day 14, when in vivo BLI appeared lower than in vitro. This difference, however, 
was not significant on day 17 (p = 0.3), perhaps due to in vitro data variability. 
Interestingly, BLI from the explant group was consistently comparable to that from the in 
vitro group, suggesting that microencapsulated cells proliferated similarly in vivo as they 
did in vitro. 
In agreement with the BLI data, comparable trends were observed between the in 
vitro and explant groups for metabolic activity on day 11 (1331 ± 254 and 1192 ± 184 
Relative Fluorescence Units (RFU), respectively, p = 0.49) and day 17 (1277 ± 278 and 
1190 ± 133 RFU, respectively, p = 0.65). Explant insulin secretory function on day 17 was 
not significantly impaired relative to in vitro microcapsules under both basal and stimulated 
conditions (explant: 192 ± 16 and 566 ± 202 U (mL capsule)-1 h-1; in vitro: 300 ± 60 and 
888 ± 226 U (mL capsule)-1 h-1; p = 0.10 and p = 0.21 for basal and stimulated conditions, 
respectively). To investigate host cellular attachment to the graft, light microscopy 
imaging, live/dead confocal imaging, and histology were performed on retrieved 
microcapsules. Light microscopy revealed no host cell attachment to the periphery of the 
microcapsules (Figure 5.2B), which was further corroborated by H&E histology images 
(Figure 5.2C). There were no observable differences between the in vitro and explant 
live/dead confocal images which clearly indicated cell growth from day 11 to 17 for both 





Figure 5.2: BLI trend comparisons between in vivo, parallel in vitro controls, and 
explanted microcapsules improved in vivo graft fate understanding. A) For 
comparison, in vivo data were normalized to day 3 in vivo BLI signals; in vitro and explant 
data were normalized to in vitro day 3 bioluminescence signals. *p<0.05: Statistical 
difference between indicated groups. In vitro and explant images of a single microcapsule 
at 10x magnification were compared on days 11 and 17 using B) light microscopy, C) H&E 
histology, and D) 2D images from live/dead confocal microscopy. 
 
 
5.4.2 Therapeutic Efficacy Evaluation 
A mixed microcapsule population was fabricated as a result of previous in vitro 
data indicating that microencapsulated Fluc cells secreted less insulin over time compared 
to EINS. The Fluc to EINS ratio was determined based on the first part of this study, in 
vivo BLI characterization, revealing that 1 mL of microencapsulated Fluc cells allowed for 
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abundant BLI signal and cell survival monitoring in vivo. Since the total transplant volume 
was fixed at 3 mL, a 1:2 ratio of Fluc:EINS microcapsules was chosen to allow for BLI 
signal and sufficient insulin output. 
Diabetic mice were injected i.p. at the 1:2 ratio of Fluc:EINS microcapsules and 
strikingly, experimental mice became normoglycemic two days later, whereas control mice 
remained hyperglycemic (Figure 5.3A); neither group received exogenous insulin before 
day 2 (Figure 5.3B). Correction was short-lived however and mice reverted back to 
hyperglycemia by day 4. Control mice exhibited significantly higher blood glucose levels 
than the experimental mice on one other day of the study (day 8). Overnight fasting 
revealed higher blood glucose levels in controls compared to experimental mice on day 17; 
exogenous insulin was withdrawn 3-4 days before fasting. 
Figure 5.3B indicates the average daily exogenous insulin administration; overall, 
control mice received 7.8-fold more insulin (p<0.001). No differences were detected in 
body weight trends between the two groups on any day of the study (Figure 5.3C). Figure 
5.3D-E depict dynamic BLI signals, indicating proliferation from day 3 to 8 and likely 




Figure 5.3: In vivo therapeutic efficacy evaluation.  A) Average blood glucose measurements per day between control mice receiving 
acellular microcapsules and experimental mice receiving EINS:Fluc microcapsules at a 1:2 ratio. B) Average exogenous Lantus® insulin 
administered per day and C) average body weight per day normalized to day -8, for control and experimental groups. D) In vivo BLI 
signals obtained from experimental mice every 4-5 days and E) representative bioluminescence images of experimental mice over time 
post-transplantation (d3, d8, d13, d17). In Figures A-C, * indicates a significant difference between the control and experimental groups 
on that day (p<0.05). In Figure D, shared symbols above bars indicate significant differences (*, # p<0.05).
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5.4.3 Explant Analyses 
On day 17 mice were euthanized, 0.5-1 mL blood was collected via cardiac 
puncture, and approximately 90% of the microcapsules were retrieved for explant analyses 
under the assumption that microcapsules remained at a 1:2, Fluc:EINS ratio. No difference 
in BLI was found between explanted (2.6±0.3 x108 photons/s) and in vitro control groups 
(2.2±0.9 x108 photons/s); live/dead images also indicated similar viability between groups 
(Figure 5.4A). From light microscopy images, the periphery of microcapsules appeared to 
be clear of any fibrosis (Figure 5.4B), which was corroborated by H&E histology (Figure 
5.4C). Live/dead and light microscopy images also appeared to indicate higher cell 
densities within microcapsules that had spent 17 days in vivo compared to those in vitro. 
Interestingly, explanted cells were 2.7 times less metabolically active with a 3-fold 
lower insulin secretion capacity compared to in vitro controls (Figure 5.5A-B). Therefore, 
when normalized to metabolic activity, there was no longer any difference in ISR between 
groups (Figure 5.5C). Similarly, explant intracellular insulin content was 2-fold lower than 
in vitro controls (Figure 5.5D), but metabolic activity normalization showed no difference 
(Figure 5.5E). Serum human insulin concentrations were high in experimental mice, 














Figure 5.4: Qualitative assessment of explanted pancreatic substitutes from treated 
mice. Representative images of explanted microencapsulated EINS/Fluc cells compared to 
in vitro control group on day 17 using A) 3D Confocal live/dead, B) light microscopy, and 






Figure 5.5: Quantitative explant analyses on day 17.  A) Metabolic activity, measured by alamarBlueTM in relative fluorescence units 
(RFU), per mL explanted microcapsules compared to in vitro controls, B) ISR per mL explanted microcapsules versus in vitro controls, 
and C) ISR per mL microcapsules normalized to metabolic activity. D) Intracellular insulin content per mL explanted versus in vitro 
microcapsules and E) intracellular normalized to metabolic activity. F) Human insulin concentrations in serum collected from control 




5.5.1 In Vivo BLI Characterization 
A BLI system was established for temporal monitoring of microencapsulated cells 
cultured in vitro and injected i.p. in vivo. Although these microencapsulated, i.p. delivered 
cell transplants are a common configuration, BLI has not previously been applied to such 
a system. BLI measurements produced signals that were consistently four orders of 
magnitude higher than background, clearly demonstrating graft survival in mice for 17 
days. In addition, comparing explanted and parallel in vitro cultures of microencapsulated 
cells revealed the potential of using this BLI method to identify probable causes for graft 
success or failure in preclinical animal models, as will be discussed. 
In islet studies, BLI capability is incorporated by isolating islets from luciferase-
expressing transgenic animals [168, 170] or by virally transducing islets from wild-type 
animals with the luciferase gene [167, 169]. Viral luciferase incorporation in primary cells 
such as islets would require genetic manipulation of the graft in every transplant procedure, 
making routine BLI application costly and time-consuming. On the other hand, 
incorporating the BLI methodology by luciferase incorporation to cell line transplants is 
inexpensive and easy especially if, as in the present study, cells retain their 
bioluminescence and functional characteristics during expansion and freezing/thawing.  
In studies of islets within TheraCyte® macrocapsule devices, BLI was used to 
investigate the long-term fate of allogeneic islets for 50 days [174], or skin fibroblasts for 
up to one year [172], after transplantation in mice or rhesus monkeys, respectively. Outside 
of diabetes therapy, only two other BLI studies have been applied to encapsulated cell 
systems for in vivo monitoring, including L929 cells suspended in Matrigel prior to 
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subcutaneous injection [171] and CHO cells in SeaPlaque agarose before i.p. 
transplantation in mice [173]. The encapsulation methods mentioned, however, were fixed 
systems that retained the cells at the graft site, which are generally less advantageous in 
sustaining therapeutic cell numbers compared to the microcapsules employed in this study 
[184]. Additionally, these studies attributed an increase or attenuation in BLI signal to cell 
growth or death without confirming this correlation in vitro and in explant studies, as was 
done in the present study. 
Propagating in vitro cultures in parallel to in vivo experiments, when feasible, can 
provide enhanced insight into graft behavior in vivo, as it did in the present study. On day 
17, in vitro, in vivo, and explant groups were evaluated and the only difference among them 
was an apparently lower in vivo BLI signal compared to the explant group. Extensive cell 
death in vivo was ruled out as the cause of this difference because bioluminescence 
indicated similar viable cell numbers between explant and in vitro groups, which was 
corroborated by comparable metabolic activity and cell secretory function. Furthermore, 
histology, live/dead, and microscopy images demonstrated virtually no host cellular 
adhesion to microcapsule surfaces, hence BLI attenuation due to fibrotic overgrowth of 
capsules was also ruled out as a cause. Loss of transplant metabolic activity in the 
peritoneal environment due to hypoxia [180] is possible but unlikely due to the long 
timescale from transplantation to BLI signal loss. The more likely cause of reduced in vivo 
bioluminescence was the movement of microcapsules away from the surface of the mouse 
abdomen. This became more apparent during microcapsule retrieval: some microcapsules 
were found beneath organs or near deeper tissues. This finding should serve as a caveat to 
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applying BLI in this particular configuration, and underline the importance of in vitro and 
explant evaluation. 
 
5.5.2 Therapeutic Efficacy Evaluation 
Enhancement and microencapsulation of the previously engineered GLUTag-EINS 
cells produced a superior graft that secreted roughly 100-fold more insulin per day than the 
macrocapsule graft formerly developed [19]. Even with dramatic secretion augmentation, 
grafts were only able to restore normoglycemia two days after transplantation in diabetic 
mice, after which grafts were likely unable to completely correct hyperglycemia [206]. 
Treated mice were, however, able to maintain body weight and avoid extreme 
hyperglycemia with significantly less exogenous insulin than controls. Fasting blood 
glucose levels and serum human insulin concentrations on day 17 revealed a still-
functioning graft in vivo and BLI was able to define temporal survival of the grafts. 
Reduced food consumption during post-surgical recovery likely contributed to the 
normoglycemia of treated mice on day 2; insulin secretion from grafts being temporarily 
sufficient to control blood glucose levels. A less likely possibility is that the graft was 
initially effective, but secretory function eventually declined to a non-therapeutic level, 
resulting in recurrence of hyperglycemia. BLI data, however, contradicted this rationale by 
indicating an approximate 2-fold increase in viable cells from day 3 to 7. It therefore 
seemed unlikely that cells, during such a proliferative time, would experience significant 
secretion impairment. 
 Fasting blood glucose data collected from experimental and control mice were 
similar to those reported in the literature for normal and STZ-diabetic mice, respectively 
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[207]. Overnight fasting elucidated that ad libitum feeding contributed significantly to 
hyperglycemia; a difference between groups is therefore more likely with controlled food 
consumption. From these findings, it was reasonably inferred that the grafts were 
insufficient in secreting the insulin levels required to overcome extreme hyperglycemia in 
freely eating diabetic mice. 
The average human insulin serum concentration in treated mice was 9-fold higher 
than that reported from diabetic mice treated with macrocapsule GLUTag-INS constructs, 
and similar to mouse insulin serum concentrations in healthy mice [20]. Blood insulin 
concentration profiles were generated to determine whether serum insulin measurements 
were likely to be accurate (Figure 5.6). Profiles were produced based on ISR data from 
explanted grafts (969 U/h), insulin clearance rates [208], and assuming all insulin secreted 
from the grafts appeared in the blood. Clearance rates of 13 and 63 mL/h were estimated 
by proportionally scaling down, based on body weight, from the physiological range of 
insulin clearance in a 70 kg man (700-3350 mL/min) [208] to a 22 g mouse. Since scaling 
down to rats is approached in this way [209], using the same method for mouse clearance 
rate estimations were assumed to be acceptable. The steady state blood insulin 
concentration range fell between 15 and 75 U/mL; the average measured serum insulin 




Figure 5.6: Blood insulin concentration profiles based on insulin secretion data from 
explanted grafts, estimated insulin clearance rates in mice, and the assumption that 
all insulin secreted from grafts appeared in the blood stream.  The following equation 







) ∙ 𝒆−𝒄∙𝒕, where Ci=blood insulin concentration, 
isr=explanted graft insulin secretion rate (969 U/h), c=clearance rate (mL/h), and t=time 
(h). An arbitrary initial blood insulin concentration of 150 U/mL was chosen and the total 
blood volume of a mouse was estimated to be 1 mL. 
 
 
The effects of mouse insulin antibodies are unknown, but human insulin RIAs have 
been shown to produce falsely high measurements due to human insulin autoantibody 
interference [210]. It is also documented that human insulin may be immunogenic in 
BALB/c mice [211], but in the present study, control mice receiving significant amounts 
of exogenous human insulin had negligible insulin serum concentrations measured by RIA. 
However, since the response in transplant groups may not be equivalent to controls, 
interference cannot be completely ruled out. Nevertheless, serum human insulin was within 
the expected concentration range and high insulin quantities in treated mice were evident 
from their comparable body weight and blood glucose trends with controls while receiving 
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almost 8-fold less insulin supplementation. Importantly, even though using human insulin-
secreting grafts is the prevalent method in the field, diabetic rodent models have shown 
resistance to exogenous porcine and human insulin, requiring 20-40 times more porcine 
insulin than the prescribed human dose [212]. This challenge, in conjunction with 
overeating, may explain why normoglycemia was not achieved here, despite very high 
serum human insulin levels. 
 Explant tests provided graft insight regarding long-term secretory function and 
viability. Interestingly, it appears that in vivo conditions caused an impairment in both 
metabolism and secretory function without instigating significant cell death. Schneider et 
al. reported similar findings after transplanting microencapsulated islets in immune 
competent diabetic mice [213]. After 10 weeks, viability was estimated at >85%, but 
insulin secretion capacity was more significantly reduced. Skiles et al. saw a similar effect 
in vitro after culturing encapsulated MIN6 aggregates under hypoxia for weeks [214, 215]. 
Although these findings relate to  cells, L cells also rely on glucose metabolism for 
stimulated secretion [216] which is disrupted under hypoxic conditions [217]. In this study, 
transplanting a large number of microencapsulated cells in the peritoneal cavity likely led 
to a significant reduction in available oxygen [180] and a consequent reduction in cell 
metabolic activity and secretion capacity. Furthermore, during BLI characterization 
studies, three times less microencapsulated cells were transplanted and no secretory or 
metabolic impairments were observed. It is therefore unlikely that simply transplanting 
higher cell numbers will be a therapeutic option. 
 Two factors of pancreatic construct fabrication in previous work contributed to its 
greatly improved secretion: 1) Additional insulin gene introduction via lentivirus allowing 
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for 1.7-2 times more insulin secretion and 2) microencapsulation for retaining monolayer 
secretion and allowing for larger transplanted cell numbers. Findings from this study imply 
that significant progress in the field is needed to fabricate a preclinically relevant 
enteroendocrine cell-based pancreatic construct. We estimate that the cells in this study 
need to secrete six times their current insulin output to limit the number of oxygen-
consuming cells and allow for a realistic 1 mL transplant volume.  
An alternative method is to complement the graft from this study with a hepatic cell 
therapy. Hepatic cells genetically engineered for glucose-responsive insulin secretion [118] 
can serve as the basal release portion of the biphasic insulin response and enteroendocrine 
cells can supply the quick-phase burst via their meal-responsive secretory granule system 
[191]. This dual cell system may relieve the secretion burden from enteroendocrine cells 




CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Conclusions 
A cell-based approach to insulin therapy for IDD patients is promising toward 
achieving the tight regulation required to maintain blood glucose concentrations within the 
normal physiologic range and eliminate the long-term secondary complications that 
significantly burden both the patient and the health care system. Clinical applicability, 
however, is still a long way off due to substantial challenges that preclude therapeutic 
efficacy and safety. As discussed earlier, the cell-based research avenues encompass a wide 
range including islet transplantation, engineeredcell lines, stem cell differentiation into 
-like cells, in vivo gene therapy, and genetic engineering of isolated autologous non- 
cells. The focus of the work in this thesis was on the latter approach because autologous 
non- cells have the potential to address both donor cell availability and immune rejection 
issues, and in particular, enteroendocrine cells were chosen as they are endogenously 
similar to  cells. The major limitations of most non- cells are their lack of glucose 
responsiveness and low levels of recombinant insulin secretion after conventional viral or 
non-viral insulin transgene incorporation. Additionally, as in all the cell-based approaches, 
little is understood regarding in vivo graft integration and the causes for failure; this further 
slows the development of clinically acceptable therapies. 
The objective of the work presented in this thesis was to substantially improve a 
previously engineered pancreatic substitute developed in our lab, in an effort to bring it the 
closest in the field to a therapeutically effective non- cell insulin therapy. To accomplish 
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this, the thesis was split into three specific aims which progressed from the genetic and 
molecular level for insulin secretion improvement on a per-cell basis, to the tissue level for 
secretion enhancement on a per-graft basis, and lastly to the preclinical level for therapeutic 
assessment in a diabetic mouse model. 
Results from the first aim, described in CHAPTER 3, provided important 
information regarding the ability of enteroendocrine L cells to secrete high levels of 
recombinant insulin. Additional incorporation of the wild-type human insulin gene via 
lentivirus transduction of the GLUTag-INS cells caused only a transient increase in insulin 
mRNA levels and secretion. Disproportionate effects of insulin mRNA on secretion led us 
to conclude that the transgene copy number is not the main step that limits insulin secretion. 
Looking at various steps within the RSP identified proinsulin processing as a likely 
limitation to high insulin production and treating cells with TSA corroborated this point. 
TSA was not only used as a tool to identify limiting steps in the RSP, but it was also 
investigated as a novel method for secretion enhancement based on its effects on insulin 
mRNA as well as downstream steps. Long-term effects of a one-time, 24 h TSA treatment 
on microencapsulated cells showed that secretion enhancement was sustained for as long 
as seven days, indicating the potential of HDACi as a treatment regimen for transplant 
recipients. It is an especially attractive approach because some oral HDACi drugs are 
already FDA-approved for cancer and epilepsy patients [218]. In an effort to identify key 
HDACs that influence RSP efficiency, cells were treated with tubacin, which had no effect. 
This was a first step in isolating the main mechanism for secretion enhancement by 
eliminating HDAC6 as playing an important role, at least in itself. 
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Overall, the combined enhancement method resulted in recombinant insulin 
secretion rates of 655-888 fmol/(106 cells·h), significantly surpassing reported secretion 
from previously engineered intestinal endocrine cells by over 6-fold. We therefore 
concluded that achieving therapeutic insulin production from L cells may be plausible by 
both increasing transgene incorporation and RSP efficiency. 
In the second aim, described in CHAPTER 4, a TEPS was developed and 
characterized for bioluminescence capabilities, controlled cell growth, and insulin 
secretory function over time. Studies for this aim were based on early passaged GLUTag-
EINS cells developed in specific aim 1, to test the effect of per-cell enhanced secretion. 
Findings revealed that stable bioluminescence was attainable and microencapsulation had 
no effect on signal or cell survival tracking abilities under conditions of normoxic growth 
and anoxia-induced death. It was therefore reasonably expected that successful real-time 
survival tracking of microencapsulated cells could be accomplished in vivo as well. 
Microencapsulation had no effect on cell insulin secretion rates and it was estimated 
that a 3 mL volume of microencapsulated GLUTag-EINS would secrete approximately 0.6 
moles of insulin per day, or 42% of the reported secretion from therapeutically successful 
TC-tet grafts [180]. It is important to keep in mind, however, that significantly more 
human than rodent insulin is required to reduce blood glucose levels in rodents [212]. This 
introduced an additional challenge to achieving therapeutic efficacy in diabetic mice. 
Compared to the GLUTag-INS-containing macrocapsule formerly developed in the lab, a 
3 mL volume of 3.3% (wt/vol) alginate microcapsules characterized by high mannuronic 
acid and cross-linked with barium ions containing GLUTag-EINS cells resulted in an 
approximate 100-fold increase in total insulin secretion output. It was therefore concluded 
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that the microcapsule configuration considerably improved the chances of observing a 
therapeutic effect of the GLUTag-EINS-containing TEPS in preclinical diabetes models. 
Finally, the third aim was covered in CHAPTER 5 and consisted of two major parts: 
sub-therapeutic in vivo BLI characterization of microencapsulated Fluc cells and in vivo 
therapeutic efficacy evaluation of the bioluminescent TEPS developed in the second aim. 
It was concluded from the first part of the study that microencapsulated cell survival is 
clearly indicated by BLI signals consistently above background levels. A caveat to this 
method, however, is that signal change or attenuation can be an artifact of microcapsule 
dispersion and increasing penetration distances. Nevertheless, inclusion of in vitro and 
explant analyses will help to clarify the observed changes in vivo. The major advantage of 
this BLI approach is that it is generalizable to any encapsulated cell technology and can 
provide insight into the causes of graft failure in an effort to accelerate the development of 
clinically acceptable cell therapies. 
In the second part of the study, it was encouraging to find that normoglycemia was 
achieved two days after i.p. injection of the alginate microcapsule constructs, even if only 
for a transient period. Although mice reverted back to the diabetic state, they required 7.8-
fold less exogenous insulin than controls, body weight was maintained, and extreme 
hyperglycemia was prevented for the duration of the study. This is the first time that an 
enteroendocrine cell-containing, controlled-growth system has shown therapeutic effects 
such as these in diabetic rodents. 
Findings from the studies in this thesis imply that significant progress in the field 
is needed to fabricate a preclinically relevant enteroendocrine cell-based pancreatic 
construct. It is estimated that the cells in this study need to secrete six times their current 
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insulin output to limit the number of oxygen-consuming cells and allow for a realistic 1 
mL transplant volume. If this cannot be attained, it is unlikely that insulin-secreting 
enteroendocrine cells can serve as a standalone therapy and supplemental strategies such 
as HDACi treatment or the incorporation of engineered hepatocytes must be developed to 
achieve therapeutic efficacy. 
 
 Future Directions 
6.2.1 Targeting Limiting Steps in the RSP for Enhanced Secretion 
After identifying proinsulin processing as a possible limiting step in the RSP of 
GLUTag-INS and GLUTag-EINS cells, a full mechanistic study should be performed to 
isolate the cause for proinsulin buildup. The challenge to this approach will be the lack in 
understanding of the L cell RSP mechanism. Based on what is known, however, there are 
various possible reasons for proinsulin buildup such as insufficient production or activity 
of prohormone convertases, proinsulin aggregation in the golgi apparatus, or improper 
vesicle packaging.  
From previous work, it appeared that L cells produced similar quantities of 
prohormone convertases PC1/3 and PC2 [18, 87]. PC1/3 is known to cleave proglucagon 
to produce GLP-1 and PC2 cleaves proglucagon to produce glucagon. Since L cells are 
programmed to secrete GLP-1 rather than glucagon, perhaps PC1/3 has higher enzymatic 
activity than PC2 or PC2 is inhibited in some manner, to allow cleavage only at the 
appropriate proglucagon site. It was demonstrated by Damholt et al. that glucagon was not 
produced in L cells even though proglucagon, PC2, and the PC2 chaperone 7b2 were 
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present [219]. This may suggest that an additional component is required to activate the 
chaperone and/or the enzyme for cleavage. 
Another consideration is whether mouse prohormone convertases PC1/3 and PC2 
can cleave human proinsulin as efficiently as they can cleave mouse proinsulin. Although 
PC1/3 and PC2 are well conserved between humans and rodents [220], the cleavage sites 
of human insulin versus mouse insulin are not completely homologous. Such a study does 
not currently exist in the literature, but perhaps it would be insightful to compare the 
cleaving efficiencies of mouse PC1/3 and PC2 on human versus mouse proinsulin, and thus 
evaluate the validity of the model used in this thesis for testing human insulin production 
in mouse L cells. 
Before investigating these specific mechanisms, however, the most enlightening 
experiment would be to tag proinsulin with a fluorescent reporter gene for transfection into 
GLUTag-INS and track its progression through the RSP using a high-speed super 
resolution microscope (20 nm resolution). A similar study by Dompierre et al. has been 
performed using a previously described imaging system [221] to track BDNF in the 
secretory granules and vesicles of neuronal cells [190]. This way, the steady state 
distribution of proinsulin may be visualized and buildup in one particular location of the 
RSP could be identified. This would help to narrow the scope of the following studies 
which would place emphasis only on the major bottleneck locations. For example, if most 
of the proinsulin was found within vesicles, investigating PC1/3 and PC2 efficiencies 
would be insightful. However, if proinsulin buildup occurs in the golgi apparatus, a 




Although enhancement of human insulin mRNA levels did not strongly contribute 
to secretion augmentation, it was a good supplement to increased RSP efficiency. 
Therefore, placing some emphasis on increasing the transcription of the insulin transgene 
would be beneficial. Perhaps coming up with better gene delivery strategies for stable 
transgene incorporation will be valuable. If this is to be pursued, the mechanism of gene 
silencing should be studied to identify the cause: lentivirus or CMV promoter? The 
lentivirus method was originally chosen based on short-term studies that showed better 
secretion after transduction with lentivirus as opposed to AAV. However, AAV 
transduction similarly increased secretion and should be studied long-term to determine 
whether silencing also occurs when using this approach. Studying the strength and stability 
of various promoters to drive insulin transgene expression would also help in optimizing 
the gene delivery strategy. Designing a study similar to the one performed by Hock et al. 
would be effective in finding the best promoter/enhancer for optimal expression of the gene 
of interest [222]. The study methodically screened several different promoters/enhancers 
to identify vectors that would provide optimal expression of the gene of interest. 
Therapeutic insulin secretion from cell lines needs to be achieved to truly prove the 
efficacy of this approach in preclinical animal models. However, once this is accomplished, 
the next hurdle will be to identify a gene delivery strategy for efficient insulin transgene 
transfer into primary enteroendocrine cells either in vivo or ex vivo. In 2010, Nikoulina et 
al. came up with a modified crypt cell isolation and culture procedure which yielded a 
primary mouse colonic crypt model enriched for enteroendocrine L cells [223]. This could 
be the best place to start in testing gene delivery strategies on primary cultures in 
preparation for an ex vivo clinical approach. Unfortunately, human L cell isolation for ex 
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vivo culture has been challenging and requires further study and optimization. A recent 
study this year, by Dame et al., reported successful methods for the isolation and in vitro 
maintenance of human colonic crypts [224]. This may therefore be a promising place to 
start in the pursuit of an ex vivo approach. 
In vivo gene delivery to L cells for stable recombinant insulin expression would be 
difficult due to the rapid turnover of the intestinal epithelium. Furthermore, a targeted 
approach must be used so as not to engineer other cell types for insulin secretion, 
potentially resulting in insulin overproduction, which could be fatal. The major benefit of 
an ex vivo over an in vivo approach, is that the cells can be genetically engineered within a 
closely controlled environment which would improve safety. The development of a TEPS 
based on ex vivo insulin transgene delivery to autologous L cells could further enhance 
safety by allowing for construct retrieval and real-time monitoring. 
 
6.2.2 HDACi Treatment for Sustained Graft Secretion Enhancement 
Studies from specific aim 1 have identified HDACi treatment as a potential method 
for enhancing graft secretion that could eventually be used in transplant recipients, 
especially since some HDAC inhibitors have already been FDA-approved for cancer and 
epilepsy patients [218]. The long-term in vitro study of microencapsulated cells was a good 
starting point which led to the discovery that a one-time 24 h TSA treatment had lasting 
secretion enhancement effects even after seven days. The next step is to design and perform 
an in vitro optimization experiment in which various conditions such as TSA dose, 
treatment time, and encapsulation configuration are evaluated. Additional in vitro studies 
could be run in parallel to these studies which test the effects of specific HDACi treatment, 
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such as the evaluation of tubacin in this work, to better identify the mechanism for insulin 
secretion augmentation. Isolating and using one HDACi for treatment rather than TSA, 
which inhibits ten different HDACs, will be a more targeted approach and likely reduce 
the possibility of side effects if brought to the clinic. 
Near the end of such in vitro optimization and characterization studies, experiments 
can move to preclinical diabetic animal models for in vivo evaluation and optimization. 
The major benefit of using HDACi drugs is that they can be orally administered. If this 
approach is indeed successful, IDD patients could undergo one surgical procedure in which 
a TEPS is transplanted and recipients may be able to take an HDACi pill regularly 
thereafter to achieve normoglycemia. This could dramatically improve IDD patient quality 
of life and reduce health care costs associated with secondary complications. 
 
6.2.3 Therapeutic Efficacy in Pair-Fed STZ-Diabetic Mice 
Based on the in vivo therapeutic efficacy study, it was highly likely that STZ-
induced diabetic mice were eating significantly more than normal, non-diabetic mice. The 
literature also suggests this, reporting that STZ-induced diabetic mice experienced 
hyperphagia [206]. This could have been a major factor contributing to the graft’s inability 
to sustain normoglycemia since significantly more insulin would be required to offset the 
extreme hyperglycemic state. In order to determine the therapeutic efficacy of a diabetic 
mouse eating normal portions, a carefully designed, pair-feeding study should be pursued. 
Pair-feeding is an experimental method that limits food intake in the same way between all 
animal groups. This could be accomplished by using a food intake monitor and controller 
module that continuously records food intake every 15 min on a computer which is 
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analyzed by the appropriate software (FDM-300s, Melquest, Toyama, Japan) [225]. This 
approach would eliminate blood glucose data variability between animals and isolate the 
real therapeutic value of the L cell graft. This approach is also clinically valid because graft 
transplantation in conjunction with a guideline for daily caloric intake could be a feasible 
option for treating IDD patients. 
 
6.2.4 A Dual Cell-Based Insulin Therapy 
The TEPS developed in this thesis, based on recombinant insulin-secreting 
enteroendocrine L cells, was insufficient as a standalone therapy in ad libitum fed STZ-
diabetic mice. An alternative method is to complement the graft from this study with a 
hepatic cell therapy. Perhaps hepatic cells genetically engineered for glucose-responsive 
insulin secretion [118] can serve as the basal release portion of the biphasic insulin 
response and enteroendocrine cells can supply the quick-phase burst via their meal-
responsive secretory granule system [191]. This dual cell system may relieve the secretion 
burden from enteroendocrine cells while improving glycemic regulation of current hepatic 
cell-based insulin therapies. Durvasula et al. computationally developed combinatorial 
insulin secretion profiles of these two cell types based on separate, experimentally 
measured secretion profiles and found that tuning of the first and second phases through 
varying cell ratios could better match  cell secretion kinetics than either one alone [191]. 
Preclinical efficacy studies must first be conducted to evaluate the potential of such 
a dual therapy approach. More specifically, studies should involve the in vivo viral delivery 
of a liver-specific, glucose responsive insulin transgene that has already been demonstrated 
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to be efficacious in STZ-diabetic rodents in vivo [226], followed by i.p. injection of the L 
cell-containing TEPS described in this thesis. 
 
As a result of the work in this thesis, exciting new research avenues have emerged, 
promising to accelerate both the understanding of important enteroendocrine cell 








Evaluating the effects of cell density on secretion function is important in 
developing an appropriate pancreatic substitute. Since genetically engineered non- cells 
secrete significantly less than islets, considerably more engineered cells must be 
transplanted for therapeutic efficacy. For this reason, it is important to determine whether 
increasing cell density inhibits recombinant L cell function and their ability to secrete 
insulin. To accomplish this, both GLUTag-INS and EINS were investigated for their 
response to increasing cell densities both in 2D and 3D. The monolayer data in this 
appendix were collected by undergraduate researcher, José Antonio Vásquez Porto-Viso. 
 
A.2 Results and Discussion 
As GLUTag-INS and EINS became more confluent in the 12-well plates, basal 
insulin secretion appeared to be affected sooner than stimulated insulin secretion, which 
only declined at very high cell densities between 1 and 1.5x106 cells/cm2 (Figure A.1). 
Interestingly, stored levels of insulin declined sooner than stimulated insulin secretion. 
These findings may suggest that basal insulin secretion was more sensitive to increasing 
cell density and that stimulated insulin secretion was only affected after stored insulin 
levels were reduced. 
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A similar experiment was also performed on microencapsulated EINS cells to 
determine whether cell proliferation could limit insulin secretion from the pancreatic 
substitute. Figure A.2 indicates that insulin secreted per graft volume increased 
disproportionately to increasing cell density within microcapsules such that the per-cell 
insulin secretion rate within microcapsules appeared to decline as cells proliferated. As 
EINS cells reached a density of approximately 1x108 cells/mL alginate, secretion appeared 
to plateau. Therefore, increasing cell numbers will not solve the issue of insufficient insulin 
secretion. This further supports research toward enhancing recombinant insulin secretion 




Figure A.1: Effects of cell density on insulin secretion function and storage capacity. GLUTag-INS and GLUTag-EINS cells were 
seeded as monolayers in 12-well plates at an initial cell density of 8x104 cells/cm2 and expanded for 10 days. On days 0, 3, 6, 8, and 10, 
ISR tests were performed, intracellular insulin collected, and viable cell numbers were quantified using trypan blue. ISR normalized to 
day 0 are indicated for A) GLUTag-INS and B) GLUTag-EINS cells. C) Intracellular insulin normalized to day 0 for both GLUTag-










Figure A.2: Effect of EINS cell density within microcapsules on insulin secretion rate 
per graft volume. EINS cells were initially microencapsulated at a density of 
approximately 1x107 cells/mL alginate. On days 1, 7, and 14 after encapsulation, 
stimulated insulin secretion samples were collected and cell density within microcapsules 
was approximated based on metabolic activity measurements using alamarBlueTM and total 
DNA using the picoGreen dsDNA kit. Three independent experiments were performed to 




APPENDIX B: WILD-TYPE INSULIN LENTIVIRUS 
TRANSDUCTION STUDIES 
 
B.1 MOI Optimization Study 
Additional insulin transgene incorporation into the GLUTag-INS cells via lentiviral 
transduction was identified by Kiranmai Durvasula as a promising strategy in our lab for 
insulin secretion enhancement. However, only a multiplicity of infection (MOI) of up to 
30 had been investigated. The purpose of this study was 1) to compare new lentivirus 
preparations (ART) to original preparations by Dr. Durvasula (KD) and 2) to find an 
optimal MOI which enhanced insulin secretion without requiring a large virus volume. 
Figure B.1 shows the results of transducing GLUTag-INS with the new ART preparations 
at MOIs of 30 and 60. Data indicate that the new lentivirus preparations were comparable 
to the previous one and that increasing the MOI to 60 had no additional enhancing effects. 
Therefore, an MOI of 30 was chosen to conserve virus. 
 
B.2 Lentivirus Transduction of Parental Enteroendocrine Cell Lines 
Insulin transgene incorporation via lentivirus transduction (LV1) into parental 
enteroendocrine cell lines, GLUTag and STC-1, was investigated (Figure B.2). Although 
insulin secretion rates and storage were significantly lower compared to GLUTag-INS and 
EINS cells, the stimulation indices were much higher and interestingly, transduced STC-1 
cells (STC-1-LV1) responded better (SI=5.6) to meat hydrolysate than transduced 
GLUTag cells (GLUTag-LV1) (SI=3). It therefore appeared that using lentivirus 
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transduction for initial insulin transgene incorporation in parental enteroendocrine cells 





Figure B.1: Determining the optimal multiplicity of infection (MOI) for the lentiviral 
transduction of GLUTag-INS with wild-type human insulin (LV-WT-INS).  GLUTag-
INS cells were seeded in a 12-well plate at a density of 1.3x105 cells/cm2, allowed to grow 
for 2 days, transduced with lentivirus and polybrene (at a final concentration of 8g/mL) 
for 24 hours, and changed to fresh medium under normal culture conditions. ISR tests were 
performed 7 days post-transduction and viable cell numbers were determined using trypan 
blue cell counting. Initials ART and KD indicate the researcher who produced and purified 
that particular lentivirus preparation. KD lentivirus preparations were used as controls 
since these were originally used by Kiranmai Durvasula to show that lentivirus 
transduction resulted in promising enhancement of insulin secretion from GLUTag-INS. 
MOIs of 30 and 60 were tested to identify which resulted in better insulin secretion 




Figure B.2: Lentivirus transduction of the parental GLUTag L cell line and the 
heterogeneous STC-1 cell line with the wild-type human insulin transgene.  Lentivirus 
transduction was performed in the same way as previously described at an MOI of 30, after 
which FACS was performed to generate a pure population of transduced cells. GLUTag 
cells were transduced with lentivirus (LV1) on day 0, ISR tests and FACS were performed 
on day 7 (GLUTag-LV1). ISR tests were then performed 3 days after FACS (GLUTag-
LV1-GFP+, p0) and again after 3 passages (GLUTag-LV1-GFP+, p3). The same 
experiment was performed on STC-1 cells except ISR tests were not performed over 
passaging of the sorted GFP+ cells. A) Insulin secretion rates from GLUTag cells 
transduced with LV1 (LV-WT-INS). B) Stored insulin levels from GLUTag-LV1-GFP+ 
cells compared to GLUTag-INS and EINS cells. C) Insulin secretion rates from STC-1 
cells transduced with LV1 (LV-WT-INS). Well 1 and well 2 were parallel wells. 
 
 
B.3 Investigating Effects of the IRES-GFP Sequence in the Lentiviral Vector 
A recent study by Mansha et al. has suggested that IRES-GFP expression vectors 
may interfere with the translation of smaller sized genes placed upstream of the IRES-GFP 
sequence [227]. To investigate whether the IRES-GFP was inhibiting insulin secretion after 
lentivirus transduction of GLUTag-INS, we removed only the IRES-GFP sequence from 
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the lentiviral vector (Schematic B.1), produced a new lentivirus which we called LV-INS, 
and tested ISR from GLUTag-INS cells transduced with either the new LV-INS or the 





Schematic B.1: The IRES-GFP sequence was removed from the lentiviral vector to 
determine its effect on insulin secretion.  LV-INS-GFP will refer to the original lentiviral 




Results from ISR tests indicated that there was no difference in insulin secretion 
rates from GLUTag-INS transduced with the new LV-INS compared to those transduced 
with the original LV-INS-GFP vector (Figure B.3). We therefore continued to use the 
original lentiviral vector in transduction studies since the IRES-GFP sequence appeared to 













Figure B.3: GLUTag-INS transduced with either LV-INS-GFP or LV-INS.  A) Insulin 
secretion rates three days post-transduction, p0 and B) Thirteen days post-transduction, p3. 
Data were normalized to the basal secretion rate of GLUTag-INS cells transduced with the 
original LV-INS-GFP lentiviral vector.
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APPENDIX C: ADDITIONAL HISTONE DEACETYLASE 
INHIBITOR STUDIES ON RECOMBINANT L CELLS 
 
C.1 Other Studied Effects of Trichostatin A 
Out of curiosity, a brief preliminary study was performed to evaluate the effect of 
TSA on glucose-responsiveness from EINS monolayers. The rationale for this was based 
on the previous findings reported in CHAPTER 3 which appeared to show a stronger effect 
of TSA on increasing basal insulin secretion levels than stimulated secretion levels. The 
question then became does TSA increase the sensitivity of these engineered L cells to 
glucose? In subjecting TSA-treated EINS cells to a 16 mM step-up in glucose 
concentration from 5 mM glucose, the secreted response was comparable to that from TSA-
treated EINS subjected to a step-up in 2% MH (Figure C.1). Non-treated cells, however, 
appeared to have less of a stimulated response to 16 mM glucose compared to 2% MH. 
Since only one experiment was performed, more studies should be carried out to clarify 
this result. 
In addition to showing glucose-responsiveness, Figure C.1 also depicts the results 
from an attempted long-term TSA study of EINS monolayers. Since it was challenging to 
passage TSA-treated EINS cells, 3D microcapsule studies were pursued as reported in 
CHAPTER 3. However, this study was interesting because it showed that after one passage, 
TSA-treated EINS cells were secreting just 1.8 to 2-fold more than the non-treated controls. 
This agrees with secretion results from one day post-encapsulation of TSA-treated EINS 
cells. These results could suggest that TSA effects decline after cell trypsinization, and an 
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approach should be investigated to allow for TSA treatment of microencapsulated cells 




Figure C.1: TSA effects on glucose-responsiveness and long-term TSA effects in EINS 
monolayers. After TSA treatment, EINS were subjected to either a 2% MH step-up or a 
16 mM glucose step-up for ISR testing. 2% MH step-up refers to cells that were subjected 
to basal medium (5 mM glucose) for 2 hours and then switched to stimulating medium (5 
mM glucose + 2% MH) for 2 hours. 16 mM glucose step-up refers to cells that were also 
subjected to 5 mM glucose basal medium, but were switched to 16 mM glucose stimulating 
medium. ISR data were normalized to non-treated, 2% MH step-up, EINS cells under each 
condition for easy comparison. Bars labeled long-term refer to TSA-treated EINS cells that 
were passaged once and grown to confluency for ISR testing. 
 
 
C.2 Another HDACi: Tubastatin A Hydrochloride 
The HDACi tubacin was chosen to inhibit the specific function of HDAC6 that 
deacetylates -tubulin and regulates vesicular trafficking. However, no effect was reported 
on GLUTag-INS or EINS insulin secretion after tubacin treatment. To investigate the role 
of HDAC6 more generally, a preliminary study was carried out involving the treatment of 
GLUTag-INS and EINS cells with tubastatin A hydrochloride, a specific inhibitor of 
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HDAC6. The basal and stimulated insulin secretion results from this study are shown in 
Figure C.2 and indicate that HDAC6 may play a very minor role in insulin secretion. More 
experiments would need to be performed for statistical comparisons, but the observed 
effects from this study were too small to be of significance in producing therapeutic insulin-




Figure C.2: A) Basal and B) stimulated insulin secretion rates from GLUTag-INS and 
EINS cells after a 24 h treatment with varying concentrations of Tubastatin A 
Hydrochloride.  Secretion data were all normalized to 0 M Tubastatin A and experiments 
were carried out in the same way as all previous HDACi treatment studies. 
 
 
C.3 Adhesive Matrices and Enhanced Secretion 
Cytoskeleton remodeling plays a major role in glucose-mediated  cell secretion 
and impacts the secretory granule system. In particular, it has been found that focal 
adhesion kinases (FAKs) affect glucose-induced cytoskeleton remodeling, insulin granule 
docking, and fusion to the plasma membrane [228]. A similar phenomenon is likely in L 
cells which also possess a secretory granule system, but release GLP-1 rather than insulin. 
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It may therefore be critical that the engineered L cells form focal adhesions in order to 
function properly. However, when cells are trypsinized and microencapsulated, they are 
essentially cells in suspension with a reduced number of focal adhesion sites as opposed to 
cells that are able to adhere to a surface as they do in monolayer cultures. This was perhaps 
why the enhanced secretion effect of TSA was lowered after trypsinization and 
microencapsulation. Maybe if more potential sites for focal adhesion were available within 
microcapsules, more insulin could be released from EINS cells. As a first, preliminary 
study, we evaluated the effect of adhesive alginate matrix microencapsulation on insulin 
storage and secretion from TSA-treated EINS cells (Figure C.3). 
Comparisons were made between Group 4 (TSA-treated EINS cells 
microencapsulated in RGD-modified LVM alginate, prepared by Dr. Hajira Ahmad, and 
cross-linked in calcium) and Group 1 (non-treated EINS cells microencapsulated in LVM 
alginate and cross-linked in barium). Comparisons were made to Group 1 because this was 
the configuration used throughout all the studies of this thesis. The black dotted lines in 
Figure C.3 indicate the secreted and stored insulin levels reported from day 1 in the long-
term TSA studies (CHAPTER 3, Figure 3.7) as a way of comparing the TSA-treated results 
in adhesive versus non-adhesive matrices. Interestingly, there appeared to be more stored 
and secreted insulin from TSA-treated EINS within an adhesive versus non-adhesive 
environment. It therefore may be interesting to pursue studies of various adhesive matrices 










Figure C.3: A) Insulin secretion rates and B) stored insulin levels of cells one day after 
microencapsulation in an adhesive matrix compared to the alginate used in the 
previous studies.  Group 1 consisted of non-treated EINS cells microencapsulated in LVM 
alginate cross-linked with barium at a density of 3x107 cells/mL alginate. Group 4 
consisted of TSA-treated EINS cells microencapsulated in LVM alginate modified to 
contain adhesive peptide RGD, and cross-linked with calcium at a density of 8x106 
cells/mL alginate. The black dotted lines in this figure indicate the secreted or stored insulin 
levels one day after EINS microencapsulation that were reported from CHAPTER 3 in the 




APPENDIX D: HISTONE DEACETYLASE INHIBITOR STUDIES 
ON BETA AND L CELL LINES 
 
D.1 Abstract 
Histone deacetylase (HDAC) inhibitors were recently identified as having 
significant clinical potential in reversing -cell functional inhibition caused by 
inflammation, a shared precursor to Type 1 and Type 2 diabetes. However, HDAC 
inhibitors are highly complex and little is known of their direct effect on cell secretion 
pathways that are important for proper blood glucose regulation. The aims of the present 
study were to investigate the effect of HDAC inhibition on -cell function and GLP-1 
secretion from L-cells. The -cell line TC-tet or the L-cell line GLUTag were exposed to 
trichostatin A for 24 hours. Effects on insulin or GLP-1 mRNA, storage, processing 
efficiency, and secretion were measured and determined by real-time PCR and ELISA. 
Viable cell numbers were counted using trypan blue. HDAC inhibition significantly 
increased secretion per viable cell in a dose-dependent manner for both cell types. Effects 
on mRNA levels were variable among cell types, but enhanced storage and secretion were 
relatively comparable. HDAC inhibition enhances - and L-cell secretion pathways in a 






The prevalence of diabetes is doubling every 10 years, with 347 million people 
affected worldwide. The World Health Organization projects that diabetes will be the 7th 
leading cause of death in 2030. Since current treatments place considerable burden on the 
healthcare system, the need exists for a novel, clinically feasible treatment that cures or 
prevents diabetes. Recently, exciting new studies have identified histone deacetylase 
(HDAC) inhibitors (HDACi) as having significant clinical potential in reversing -cell 
functional inhibition caused by inflammation, a shared precursor to Type 1 and Type 2 
diabetes. Since some small molecule HDACi drugs have been FDA-approved for epilepsy 
and cancer therapies, repurposing their use for diabetes treatment is a tangible option. 
Several small molecule HDACi drugs are currently under clinical investigation to 
reactivate repressed gene expression in patients with cancer and neurodegenerative 
disorders such as Parkinson’s or Alzheimer’s disease. It is now recognized that acetylation 
also plays an important role in diabetes etiology. For example, it regulates the master 
transcription factor in the inflammation nuclear factor, (NF)-kB, which is critical to 
inducing -cell death when activated [229, 230]. Two groups have demonstrated in vitro 
that HDACi treatment indeed helps to prevent cytokine-induced -cell death [231, 232]. 
An in vivo study reported that twice weekly i.p. injections of HDACi in mice that 
spontaneously developed diabetes reduced blood glucose and T-cell mediated -cell 
destruction [233]. In addition to this effect, HDACi drugs have shown evidence of 
alleviating insulin resistance and glucose uptake in skeletal muscle and liver cells [234, 
235]. HDACi effects on other cells whose functions are critical to -cell function, such as 
glucagon-like peptide-1 (GLP-1)-secreting intestinal L-cells, have not been investigated. 
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Although HDACs are known to play a key role in chromatin remodeling by acting 
on histone proteins, recent findings have shown that HDACs also act on 875 other classes 
of proteins [197]. These small molecule inhibitors are therefore inherently non-specific, 
complex, and can have many effects other than anti-inflammation in diabetes patients. As 
-cell function is critical for proper blood glucose regulation, investigating the direct 
HDACi effects on -cell function is among the most vital of studies toward developing a 
clinically acceptable treatment. Some studies have observed Trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA), or sodium butyrate (NaB) effects on -cell line 
or islet function, but only as an aside to their primary investigation in determining anti-
inflammatory effects [231, 232] or developing a pre-culture method for improved islet 
transplantation [189]. The reported effects have therefore been contradictory. Luef et al. 
studied the direct effects of valproic acid (VPA) on human islets to investigate the cause 
for increased postprandial insulin levels in epilepsy patients treated with VPA [188]. The 
group reported a dose-dependent increase in secreted insulin from islets incubated with 
VPA, but this effect was attributed to the behavior of VPA as a fatty acid derivative rather 
than as an HDACi. In support of using HDACi as a novel diabetes treatment, Christensen 
et al. state that further investigation into HDACi effects on the secretion pathway of -cells 
is necessary [236]. 
The overall objective of this work was to fill in the gap in the literature regarding 
HDACi effects on the function of cells that are important in the prevention or treatment of 
diabetes. In this work, we report the effects of HDACi treatment on the secretion pathways 
of murine - and L-cell lines. The impact of this work towards developing HDACi 
prevention and treatment options for diabetes patients are discussed. 
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D.3 Materials and methods 
Cells Murine insulinoma TC-tet cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma, St. Louis MO) with 25 mM glucose and supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S), and L-glutamine to a final 
concentration of 6 mM. GLUTag cells were cultured as in [191] using DMEM with 25 mM 
glucose, without L-glutamine (Corning cellgro, Manassas, VA, Cat. #15-017), and 
supplemented with 10% FBS and 1% P/S. Cell cultures were propagated in a humidified 
incubator at 37oC/5% CO2. 
 
Relative mRNA quantitation Cells were harvested for RNA isolation using the E.Z.N.A 
Total RNA Kit I (OMEGA bio-tek, Norcross, GA) followed by cDNA synthesis using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY). 
cDNA was synthesized from 1g of RNA and the manufacturer’s protocols were followed 
closely. Real-time, relative quantitation of mRNA was accomplished using the SYBR 
Select Master Mix (Applied Biosystems) and the StepOnePlus Real-Time PCR System 
(Life Technologies) for measurement and comparative CT method analysis. Mouse insulin 
(INS-1) and GLP-1 primers were designed using National Center for Biotechnology 
Information’s (NCBI’s) Primer-BLAST design software and mouse beta-actin (ACTB) 
primers were used as endogenous controls. Primer sequences were as follows: forward 
mouse insulin-1 5’-CTT GTT GGT GCA CTT CCT AC-3’, reverse mouse insulin-1 5’-
TGC AGT AGT TCT CCA GCT GG-3’, forward GLP-1 5’-ACA GCA AAT ACC TGG 
ACT CCC GCC GT-3’, reverse GLP-1 5’-CCT CGG CCT TTC ACC AGC CAA GCA A-
3’, forward mouse ACTB 5’-GCA CAG CTT CTT TGC AGC TC-3’, reverse mouse 
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ACTB 5’-CTT TGC ACA TGC CGG AGC C-3’. All primers were purchased from 
Eurofins MWG Operon, Huntsville, AL and used at 300 nM concentrations. 
 
Dose-response curves Dose-response curves were constructed to determine the effect of 
varying TSA (Sigma) concentrations on secretion and viable cell numbers. TSA was 
carefully chosen for these studies due to its similarity in structure to the FDA-approved 
HDACi drug, Vorinostat [237]. Serial dilutions of TSA were made in dimethyl sulfoxide 
(DMSO; Sigma) starting at 2.5 M (six concentrations were tested: 0, 0.156, 0.313, 0.625, 
1.25, and 2.5 M). After a 24 hour incubation at these varying TSA concentrations, wells 
were washed twice in Dulbecco’s Phosphate-Buffered Solution (DPBS; Corning cellgro) 
containing calcium and magnesium to remove any dead cells and changed to stimulating 
medium (TC-tet: 16.7 mM glucose for 30 minutes, GLUTag: 5 mM glucose + 2% MH 
for 2 hours). Medium samples were collected after the incubation periods and cells were 
subsequently trypsinized for trypan blue (Sigma) viable cell counting using a 
hemocytometer for data normalization. 
 
Effects on secretion pathways To study the secretion pathway, cells were seeded in 12-well 
plates (TC-tet: 1.8x105 cells/cm2, GLUTag: 2.1x105 cells/cm2) two days before TSA 
treatment. Initial cell densities were chosen to achieve a similar level of confluency, 
approximately 85%, among groups on the day of treatment. On day 0, culture medium was 
changed to fresh in each well and TSA was added at an intermediate concentration of 0.625 
M. Non-treated control groups were used for direct comparisons. On day 1, insulin or 
GLP-1 secretion rate tests were performed and cells in parallel wells were harvested for 
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intracellular insulin or GLP-1 and total RNA collection. To collect intracellular proteins, 
TSA and non-treated cell pellets were lysed using the Mammalian Cell Lysis Kit (Sigma). 
Proinsulin and insulin concentrations were measured from TC-tet samples by Mouse 
Insulin and Rat/Mouse Proinsulin ELISA kits (Mercodia Inc., Winston Salem, NC) and 
GLP-1 concentrations were measured from GLUTag samples by GLP-1 (Active) ELISA 
(Mercodia Inc.). 
Effects of tubacin (Sigma) were investigated to determine the specific role of 
HDAC6 in the effects observed from TSA treatment, which acts on HDACs1-10. This 
choice of HDACi is based on reports that inhibition of HDAC6, a cytoplasmic HDAC, 
increases vesicular transport and secretion of hormones in neuroendocrine cells by 
increasing acetylated -tubulin levels [190]. Tubacin treatment was identical to TSA 
treatment, except a final concentration of 4 M was used. This concentration was estimated 
based on cytoblot analyses of TSA and tubacin effects on acetylated tubulin levels in A549 
cells. An approximate tubacin treatment of 4 M caused a similar increase in acetylated -
tubulin levels as TSA at around 0.625 M [193]. Tests such as this one, with other specific 
HDACi, may provide more insight into the main mechanisms for the observed effects of 
TSA treatment. 
 
Insulin secretion rate test ISR tests performed on TC-tet cells involved subjecting cells 
to basal conditions (DMEM with 0 mM glucose) for one hour followed by a thirty minute 
step-up period under stimulating conditions (DMEM with 16.7 mM glucose). Secretion 
tests on GLUTag cells involved subjecting cells to basal conditions (DMEM with 5mM 
glucose) for two hours followed by a two hour step-up period under stimulating conditions 
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(basal + 2% meat hydrolysate (MH); Sigma). Media samples were taken before and after 
each incubation period for rate determinations. 
 
Statistical analyses All data were analyzed using Minitab software (Minitab, Inc., State 
College, PA) and reported as mean ± SEM; each mean was the average of data from three 
or more independent experiments. Significance was determined using a one-way analysis 
of variance (ANOVA) with the general linear model, with significance defined as p≤0.05. 
 
D.4 Results 
Dose-response curves After 24 hours of treating TC-tet and GLUTag cells with varying 
TSA concentrations, a similar dose-dependent response was observed between stimulated 
insulin and GLP-1 secretion per viable cell; effects on viable cell numbers also followed 
comparable trends between groups (Figure D.1). At a TSA concentration of 0.313 M or 
higher, both groups secreted significantly more than non-treated controls and appeared to 
plateau near a TSA concentration of 1.25 M. The inverse was true for TSA effects on 
viable cell numbers which were significantly lower than non-treated controls at and above 
0.313 M TSA, plateauing near 1.25 M TSA. The viability, or fraction of viable cells 
from the total cell number, after TSA treatment only declined slightly and plateaued around 
80% for all groups, suggesting that secretion tests were performed on a population 




Figure D.1: TSA dose-response curves for TC-tet and GLUTag L-cells. Effects of 24 
hour TSA treatment on A) secretion and B) viable cell numbers. Accumulated GLP-1 
released from GLUTag cells was measured after a 2 hour incubation in medium containing 
5 mM glucose and 2% MH. Accumulated insulin released from TC-tet cells was measured 
after a 30 minute incubation in medium containing 16.7 mM glucose. Accumulated 
secretion data were normalized to viable cell numbers prior to normalization of all data to 




Effects on secretion pathways To avoid excessive toxicity, an intermediate concentration 
of 0.625 M TSA was chosen to specifically assess HDACi effects on insulin and GLP-1 
mRNA, storage, and secretion rates. It was surprising to find that TSA-treated - and L-
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cells had lower levels of insulin (78% of control) and GLP-1 (36% of control) mRNA, 




Figure D.2: Relative quantitation of INS-1 mouse insulin mRNA in TSA-treated TC-
tet cells and GLP-1 mRNA in TSA-treated GLUTag cells relative to their non-treated 
controls under basal and stimulated conditions. A one hour incubation in the following 
medium for each cell type was performed prior to total RNA collection. Asterisks indicate 
statistical difference from non-treated control groups (*p<0.05). 
 
 
TSA treatment of TC-tet cells caused a 2.5-fold increase in stored insulin and a 2-
fold increase in glucose-stimulated insulin secretion but had no significant effect on 
constitutive insulin secretion under basal conditions (Figure D.3; TC-tet). TSA treatment 
of GLUTag cells also increased stored and MH-stimulated GLP-1 secretion by 2 and 1.9-
fold, respectively, but had an even greater effect on basal GLP-1 secretion (5 mM glucose) 
which increased by almost 9-fold (Figure D.3; GLUTag). The effect on stimulated 
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secretion, however, was only significant with 90% confidence (p=0.09). No significant 




Figure D.3: TSA (0.625 mM) and tubacin (4 mM) effects on stored and secreted mouse 
insulin from TC-tet cells and GLP-1 from GLUTag cells. All data were normalized to 
viable cell number prior to normalization to non-treated controls. Asterisks indicate 
statistical difference from control group under each condition (*p<0.05). 
 
 
A small, but significant, 10% increase in secreted proinsulin to insulin conversion 
was found in TSA-treated TC-tet cells under 16.7 mM glucose conditions (Figure D.4A), 
but no difference was detected in stored insulin processing efficiency relative to non-
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treated controls (Figure D.4). Processing efficiencies of proglucagon to GLP-1 in parental 
GLUTag cells were not determined because commercially available proglucagon ELISA 
kits (RayBiotech, Inc., Norcross, GA) are expected to measure other small peptides such 
as glicentin and glicentin-related polypeptide (GRPP) that are synthesized from 





Figure D.4: Effects of TSA on the efficiency of proinsulin to insulin processing of 
basal/stimulated secretion and intracellular storage in TC-tet cells. Asterisk indicates 





With the recent presence of HDAC in the diabetes literature [236], and the 
newfound potential for HDACi therapy to protect cytokine-mediated -cell death [231, 
232], there is little information regarding the impact of HDACi on other important factors 
that play major roles in diabetes. In this work, we have demonstrated the potential benefits 
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of HDACi for the direct and indirect functional enhancement of -cells through increasing 
insulin storage and secretion capacity as well as GLP-1 storage and secretion from L-cells.  
Enhancing effects of TSA on TC-tet cells in this study are in accordance with 
reports of a dose-dependent increase in insulin secretion from human islets treated with 
VPA [188] and increased insulin secretion after the use of a culture technique on rat islets 
involving 0.1 M TSA treatment for 24 hours [189]. The specific effects of TSA on rat 
islets in the latter study, however, were not assessed and results from the former study were 
attributed to the structural similarity of VPA to free fatty acid secretagogues. In contrast to 
these studies, Larsen et al. observed a reduction in insulin release from rat INS-1 -cells 
treated with 0.2 M TSA for two days. The timescale for the experiment was properly 
designed, as it was meant to test effects of TSA on cytokine-mediated apoptosis, but it was 
inappropriately long for assessing the direct effects of TSA on -cell function. 
Additionally, -cell secretion was not normalized to viable cell numbers for appropriate 
comparisons of the functional effects of TSA-treated and non-treated populations on a per-
cell basis. For these reasons, conclusions of direct TSA effects on -cells could not be 
made with certainty. 
 The observed 21% reduction in insulin mRNA levels in TSA-treated TC-tet cells 
and the 64% reduction in GLP-1 mRNA levels in TSA-treated GLUTag cells are not yet 
understood and investigation in future studies is needed, as they are beyond the scope of 
this study. There are various possible explanations such as cellular mRNA degradation due 
to TSA-induced apoptosis [238], direct effects of TSA on mRNA stability [239], or 
repressed gene transcription which is a common effect of HDACi [240]. The first reason 
is unlikely since global mRNA degradation due to early-stage apoptosis should cause the 
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endogenous control, actin-beta mRNA, to degrade as well, but there was no evidence of 
this from the PCR results (mean (SD) CT values for TC-tet: ACTB- 25.4 (3.9), ACTB+ 
25.7 (3.9); p=0.9; n=3 and GLUTag: ACTB- 19.1 (0.5), ACTB+ 19.5 (1.1); p=0.4; n=5). 
Apoptosis therefore was not measured, especially since cell death and apoptotic effects of 
HDACi have already been well studied [231, 232]. 
 The purpose of using the TC-tet cell line as opposed to islets in this study was to 
simply investigate the direct effects of HDACi on -cell function. HDACi effects on islets 
are highly complex and change in insulin secretion and expression may be an indirect effect 
of TSA stress on neighboring cells. A limitation to studying the -cell line, however, is that 
it is less clinically relevant and studies in islets will still need to be performed. 
 Oral HDACi administration could impact various cells within the body. In diabetes 
patients, proper GLP-1 secretion from intestinal L-cells is critical to glucose-stimulated -
cell function. Interestingly enough, GLP-1 increases in vitro global acetylation of histone 
H3 in -cells [241] and may therefore be acting on mechanisms similar to the ones which 
HDACi act on. As expected, based on secretion pathway similarities between - and L-
cells, TSA had similar enhancing effects on GLUTag cells. However, a stronger effect on 
glucose-induced GLP-1 secretion was observed than on MH-induced secretion. Although 
the stimulation index was lost when inducing with peptides like MH, perhaps a shift to 
glucose-controlled secretion occurred after TSA treatment. Significantly higher secretion 
of GLP-1 in response to glucose in type 2 diabetes patients would be extremely beneficial 
in the local stimulation of -cell insulin secretion for improved glucose regulation. This 
method would be a better alternative to the oral GLP-1 analog therapies that have 
suboptimal pharmacokinetics and blood glucose regulation compared to natural body 
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functions. To clarify the impact of HDACi on L-cell glucose-responsiveness, further 
investigation is necessary. In addition, animal studies should be performed to assess the 
clinical consequences of losing the GLP-1 burst response to peptides and gaining glucose-
responsiveness. 
Evidence from this study further supports the potential role of HDACi therapy in 
preventing or treating diabetes mellitus by expanding knowledge in the field about the 
additional benefits of HDACi on - and L-cell function. To determine clinical feasibility, 
preclinical effects of FDA-approved HDACi like Vorinostat, with structural similarities to 
TSA, should be studied in non-obese diabetic (NOD) mice to evaluate diabetes prevention 




APPENDIX E: ADDITIONAL BIOLUMINESCENCE STUDIES 
 
E.1 AAV Transduction for Luciferase Gene Incorporation 
Prior to using the lentivirus for luciferase reporter gene incorporation, AAV 
transduction of GLUTag-INS was investigated. AAV transduction was performed in the 
same way as with lentivirus, but the MOI used for this study was much higher (MOI 2000). 
Even with such a high MOI, luciferase delivery via AAV resulted in an average of only 
1.6x106 photons/s (Figure E.1) compared to over 2.4x107 photons/s emitted from a similar 
number of lentivirally-transduced EINS cells at an MOI of 30. In addition, after only one 
passage, AAV-transduced GLUTag-INS no longer expressed bioluminescence. For these 

















Figure E.1: Transduction of GLUTag-INS cells with an AAV containing the luciferase 
reporter gene. Passage 0 = 3 days post-transduction, Passage 1 = 5 days post-transduction. 
Initial cell seeding density was 7.9x104 cells/cm2. 
 
 
E.2 Optimal Time for Bioluminescence Imaging 
A brief preliminary study was performed to determine the optimal bioluminescence 
imaging time after i.p. injection of luciferin in mice (Figure E.2). As strong 
bioluminescence signal was observed after only 5 minutes post-luciferin injection, it was 
chosen as the imaging time for all studies. A short imaging time was favorable in order to 











Figure E.2: BLI over the course of 20 minutes in three mice after luciferin injection. 
Two of the mice (Mouse 1 and 2) were i.p. injected with 1 mL of microencapsulated Fluc 
cells and one mouse (Negative control) was injected i.p. with 1 mL of cell-free 
microcapsules. Representative images of the same mouse imaged at 5, 10, 15, and 20 
minutes after luciferin injection are shown at the top of this figure to indicate the strength 
of BLI. Quantitative bioluminescence over time for each mouse is indicated in the graph 




APPENDIX F: OPTIMIZATION OF THERAPEUTIC EFFICACY 
STUDY 
 
F.1 Results from the First Therapeutic Efficacy Study 
The first therapeutic efficacy study allowed for proper optimization of the protocol. 
It was clear from the data represented in Figure F.1 that mice became extremely 
hyperglycemic after an STZ injection of 230 mg/kg. On day 0, all but two of the mice were 
giving readings of “HI” on the glucometer. However, mice receiving the 
microencapsulated TC-tet cells were able to restore normoglycemia while the EINS or 
Fluc-receiving mice continued to read “HI” on the glucometer. Since mice were in this 
state for three consecutive days after transplantation, they were sacrificed according to the 
IACUC protocol. Promising pieces of data were that mice receiving EINS or Fluc cells 






Figure F.1: Results from the first therapeutic efficacy experiment. Mice were injected i.p. with STZ (230 mg/kg) four days before 
the surgery to induce diabetes. Three groups were evaluated: 2 mice received 3 mL microencapsulated EINS cells, 2 mice received 3 
mL microencapsulated Fluc cells, and 2 mice received 0.4 mL microencapsulated TC-tet cells to serve as positive controls. Results are 
shown as blood glucose levels (upper and lower left), body weight (upper right), and serum human insulin concentration at the end of 
the study (lower right). The table indicates the mice that had blood glucose level readings of “HI” by the glucometer on day 0. These 




F.2 Exogenous Insulin Administration 
In the second therapeutic efficacy study, the following changes were made: 1) 
exogenous insulin was administered (long-acting human insulin-Lantus®) to avoid extreme 
hyperglycemia and 2) a 2:1 ratio of either GLUTag-INS:Fluc or EINS:Fluc microcapsules 
were transplanted due to in vitro studies indicating that EINS functioned better over time 
in microcapsules compared to Fluc (CHAPTER 4, Figure 4.6). Although exogenous insulin 
administration reduced extreme hyperglycemia, the issue of hypoglycemia arose since 
dosing of human insulin was difficult in the mice (Figure F.2). It appeared that 
administering 2 U of Lantus® insulin in the span of 24 hours was too high for Mouse 2 
which became extremely hypoglycemic on day 4 and had to be euthanized. Even less than 
1.5 U caused Mouse 3 to become extremely hypoglycemic on day 10. For this reason, we 
decided that lowering the STZ dose, as well as the exogenous insulin dose administered, 





Figure F.2: Blood glucose and doses of exogenous insulin administered during the second therapeutic efficacy test. STZ was 
injected i.p. in four mice 7 days before surgery. On day 0, mouse 1 and 3 were transplanted with 3 mL microencapsulated EINS (2 mL) 
and Fluc (1 mL) cells and mouse 2 and 4 were transplanted with 3 mL microencapsulated GLUTag-INS (2 mL) and Fluc (1 mL) cells. 
Black bars indicate blood glucose levels (left axis) and the grey bars indicate the dose of exogenous insulin that was administered (right 
axis). An empty space before the end of the study period of 14 days indicates that the mouse was euthanized due to extreme 
hypoglycemia, resulting from exogenous insulin administration.
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F.3 Optimizing the STZ Dose 
A brief study consisting of three mice was performed to determine the lowest STZ 
dose that would still induce diabetes (>350 mg/dl blood glucose concentration). There 
appeared to be a dose-dependent response to STZ injection and lower doses increased the 
time needed to reach a diabetic state (Figure F.3). In addition, lower doses showed less of 
a decline in mouse body weight. The lowest dose, 150 mg/kg STZ, did not induce diabetes. 
The high dose, 210 mg/kg STZ, made the mouse diabetic one day after injection. On the 
other hand, the intermediate dose of 180 mg/kg, made the mouse diabetic three days after 
injection and most of the time hyperglycemic blood glucose levels were either comparable 
or lower than the mouse that received the highest dose. In addition, the two diabetic mice 
maintained reasonable hyperglycemic blood glucose levels when administered 
approximately 2 U of exogenous insulin every two days. 
Based on this and the previous optimization studies, therapeutic efficacy studies 
were carried out as follows: 1) Mice were made diabetic via i.p. STZ injection at 180 mg/kg 
to avoid extreme hyperglycemia, 2) non-treated diabetic mice were administered 2 U of 
exogenous insulin if blood glucose levels were >350 mg/dl and treated diabetic mice were 
only administered 1 U of exogenous insulin if blood glucose levels were >450 mg/dl for 
two consecutive days in order to avoid extreme hypoglycemia, and 3) mice were 





Figure F.3: Effect of STZ dose on blood glucose and body weight over 12 days. Three mice were injected i.p. with STZ at doses 
150, 180, and 210 mg/kg. A) Blood glucose levels versus STZ dose three days after STZ-injection. The last data point was added (230 
mg/kg) based on previous studies. B) Mouse body weight over time at various STZ doses. C) Blood glucose levels over time at various 
STZ doses. The numbers above bars represent the U of insulin administered to the mouse on that day.
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APPENDIX G: DATA USED FOR NORMALIZATION IN 
LONG-TERM HDACI STUDY 
 
 
Figure G.1: Long-term TSA effects on basal and stimulated ISR normalized to 
alamarBlueTM, intracellular insulin content normalized to alamarBlueTM, and insulin 
mRNA from alginate microencapsulated EINS cells over 14 days. To make TSA fold-
increase comparisons among secreted, intracellular, and mRNA groups, all data were 
normalized to non-treated microencapsulated EINS cells cultured and tested in parallel to 
treated groups. Asterisks indicate a statistical difference from day 1 within each respective 
measurement (p<0.05). See APPENDIX G for the table of values from non-treated groups 
that were used for normalization. 
 
 
Table G.1: Data reported as mean (SEM) from non-treated microencapsulated EINS 
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